ARILAMIDINAS FUNGICIDAS

Arylamidines are developed to address the need for broad-spectrum fungicides with low application rates, effectively controlling fungal diseases in agriculture by formulating them into agricultural compositions for plants and growth media.

BR112025024332A2Pending Publication Date: 2026-11-10CORTEVA AGRISCIENCE LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025024332
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-11
Filing Date
2024-05-03
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

There is a need for fungicides with improved fungicidal activity against a broader spectrum of agricultural pathogens and at lower application rates, including activity against specific fungal diseases such as wheat leaf blight, nettle blotch of barley, ramularia leaf spot in barley, barley scald, cercospora leaf spot in beetroot, anthracnose of cucurbits, and rice blast.

Method used

Development of arylamidines, including compounds of Formula I and their acceptable salts, solvates, and hydrates, which are formulated into agricultural compositions for application on plants, seeds, and growth media to control fungal diseases.

Benefits of technology

The arylamidines demonstrate significant fungicidal activity against a wide range of fungal pathogens, including wheat leaf blight, barley scald, and rice blast, with low phytotoxicity and effective at lower application rates.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This disclosure relates to aryl amidines of Formula I and their use as fungicides.
Need to check novelty before this filing date? Find Prior Art

Description

1 / 77 Arylamides fungicides CROSS-REFERENCE TO RELATED REQUESTS

[0001] This application claims priority and benefit of Provisional Patent Application Serial No. US 63 / 501,465, filed May 11, 2023, the full disclosure of which is expressly incorporated by reference herein. BACKGROUND AND SUMMARY

[0002] Fungicides are compounds, of natural or synthetic origin, that act to protect and / or cure plants against damage caused by agriculturally relevant fungi. In general, no fungicide is useful in all situations. Consequently, research is ongoing to produce fungicides that may perform better (e.g., better efficacy at lower application rates), be easier to use, and cost less.

[0003] The present disclosure relates to arylamidines and their use as fungicides. The disclosure also relates to processes for the preparation of these compounds, to agricultural compositions comprising them, and to their use in the treatment and control of fungal diseases or disorders in agriculture.

[0004] Publication of PCT Application No. WO 2020 / 237131 A1 (hereinafter “the application '131”) describes a series of fungicidal compounds. Three particular compounds disclosed in application '131 are 3-(trifluoromethyl)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate (Example 25), 4-(trifluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate (Example 27) and 3-(trifluoromethyl)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Example 494), whose structures are shown below. Petition 870250102165, dated 07 / 11 / 2025, page 80 / 176 2 / 77 Example 25 Example 27 Example 494 Examples 25, 27 and 494 of document WO 2020 / 237131 Al

[0005] The compounds described in application '131 have demonstrated activity against one or more fungi relevant to agriculture, such as wheat leaf septoria caused by Zymoseptoria tritici, wheat leaf brown rust caused by Puccinia triticina, Asian soybean rust caused by Phakopsora pachyrhizi, barley scald caused by Rhynchosporium secalis and brown spot caused by Cochliobolus sativus.

[0006] There is still a need for antifungal compounds that demonstrate an improved spectrum of fungicidal activity and increased fungicidal activity at lower application rates, such as activity against wheat leaf blight caused by Zymoseptoria tritici, nettle blotch of barley caused by Pyrenophora teres, ramularia leaf spot in barley caused by Ramularia colocygni, barley scald caused by Rhynchosporium secalis, Petition 870250102165, dated 07 / 11 / 2025, page 81 / 176 3 / 77 Cercospora leaf spot in beetroot caused by Cercospora beticola, anthracnose of cucurbits caused by Colletotrichum orbiculare, rice blast caused by Magnaporthe oryzae, and barley rust caused by Puccinia hordei.

[0007] Therefore, an objective of the present disclosure is to provide compounds that meet one or more of the aforementioned needs.

[0008] In one embodiment, the present disclosure provides a compound of Formula I: Formula I or an acceptable salt, solvate or hydrate thereof.

[0009] In another embodiment, the present disclosure provides a compound of Formula I, wherein acceptable salts of Formula I include, but are not limited to, hydrochloride, hydrobromide, sulfate, phosphate, trifluoroacetate, formate, citrate, maleate, oxalate, tartrate, fumarate, benzenesulfonate, p-toluenesulfonate, succinate, methanesulfonate, L-malate, acetate, benzoate or 4-hydroxybenzoate.

[0010] In another embodiment, the present disclosure provides a compound of Formula I, wherein the acceptable salt is the hydrochloride salt (Formula IB): The ch3 Petition 870250102165, dated 07 / 11 / 2025, page 82 / 176 4 / 77 IB Formula

[0011] In another embodiment, the present disclosure provides an agricultural composition comprising a compound of Formula I as defined herein or an acceptable salt, solvate or hydrate thereof and one or more phytologically acceptable carrier materials.

[0012] In another embodiment, the present disclosure provides a compound of Formula I as defined herein or an acceptable salt, solvate or hydrate thereof or an agricultural composition as defined herein, for use in the treatment or prevention of fungal diseases or disorders in or on a plant.

[0013] Yet another embodiment of the present disclosure may include a method for controlling or preventing fungal attack on a plant, wherein the method includes the steps of applying an effective amount as a fungicide of one of the compounds described above to at least one of the fungus, a seed, the plant and an area adjacent to the plant.

[0014] Another embodiment of the present disclosure may include a method for controlling or preventing fungal attack on a plant, wherein the method includes the steps of applying an effective amount as a fungicide of one of the compounds described above to a growth medium adapted for growing a plant or a seed.

[0015] Another embodiment of the present disclosure is the use of a compound of Formula I, as defined herein, or an acceptable salt, solvate or hydrate thereof, for the protection of a plant against attack by a phytopathogenic organism or the treatment of a plant infested by a phytopathogenic organism, comprising the application of a compound of Formula I, as defined herein. Petition 870250102165, dated 07 / 11 / 2025, page 83 / 176 5 / 77 present document or an acceptable salt, solvate or hydrate thereof or a composition comprising the compound in soil, a plant, a part of a plant, foliage and / or roots.

[0016] Additionally, another embodiment of the present disclosure is a composition useful for protecting a plant against attack by a phytopathogenic organism and / or treating a plant infested by a phytopathogenic organism, comprising a compound of Formula I and a phytologically acceptable carrier material.

[0017] The present disclosure further provides a method of synthesizing a compound of Formula I or an acceptable salt, solvate or hydrate thereof, as defined herein.

[0018] In another embodiment, the present disclosure provides a compound of Formula I or an acceptable salt, solvate or hydrate thereof, obtained by or directly obtained by a synthesis method as defined herein.

[0019] Like those in the compounds of application '131, the compounds present have activity against one or more fungi relevant to agriculture, such as tomato black spot caused by Alternaria solani, gray mold caused by Botrytis cinerea, powdery mildew of cucurbits caused by Podosphaera xanthii, soybean leaf blight caused by Cercospora kikuchii, target spot of soybean caused by Corynespora cassiicola, brown spot of soybean caused by Septoria glycines and brown leaf rust of wheat caused by Puccinia triticina.

[0020] The terms “ambient temperature” and “room temperature” refer to temperatures that are in the range of about 20 °C to about 24 °C. Petition 870250102165, dated 07 / 11 / 2025, p. 84 / 176 6 / 77

[0021] The terms “phytologically acceptable carrier”, “phytologically acceptable carrier material”, “carrier acceptable for agriculture” or “carrier material acceptable for agriculture” refer to a carrier or excipient that is useful in the preparation of an agricultural composition and is generally not phytotoxic to valuable crops.

[0022] The term “crystalline” refers to a form of solid state where molecules are arranged to form a crystalline lattice comprising distinguishable unit cells. A particular crystalline form can be identified by specific diffraction peaks when subjected to X-ray radiation.

[0023] Throughout the disclosure, in a solvate of Formula I or an acceptable salt thereof, the ratio of solvent molecules to the compound of Formula I or an acceptable salt thereof may be, but not limited to, 1:2, 1:1 or 2:1.

[0024] Throughout the disclosure, in a hydrate of Formula I or an acceptable salt or solvate thereof, the ratio of water molecules to the compound of Formula I or an acceptable salt or solvate thereof may be, but not limited to, 1:2 (hemihydrate), 1:1 (monohydrate), 2:1 (dihydrate).

[0025] Throughout the disclosure, reference to Formula I compound or Formula I compounds is read as also including acceptable salts, solvates or hydrates thereof, unless otherwise indicated in this document or clearly contradicted by the context.

[0026] Throughout the disclosure, the reference to the compound or compounds of Formula I is read as also including all regioisomers, structural isomers, geometric isomers, rotational isomers, tautomers and Petition 870250102165, dated 07 / 11 / 2025, p. 85 / 176 7 / 77 stereoisomers, for example, diastereomers, enantiomers and mixtures thereof.

[0027] Development compounds may also contain linkages (e.g., carbon-carbon linkages) in which rotation of the linkage is restricted around that specific linkage, for example, restriction resulting from the presence of a ring or a double bond. Consequently, any cis / trans and E / Z isomers are expressly included in this disclosure.

[0028] The compounds of the disclosure may also be present in multiple tautomeric forms. When one or more tautomeric forms exist, the disclosure expressly includes all such tautomeric forms of the compounds described in this document, even if only a single tautomeric form can be represented.

[0029] The compounds of the present disclosure may exist in an amorphous solid form or as an oil.

[0030] The compounds of the present disclosure may exist in one or more crystalline or polymorphic forms. All crystalline forms and polymorphs of the compounds of the disclosure are expressly included in the present disclosure.

[0031] In one embodiment, the present disclosure provides a crystalline form of 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate (Formula I).

[0032] In another embodiment, the crystalline form of 4(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate (Formula I) is an anhydrous, solvent-free crystalline polymorphic form.

[0033] In another embodiment, the crystalline form is the Petition 870250102165, dated 07 / 11 / 2025, page 86 / 176 8 / 77 Form A of the crystalline polymorph (referred to herein as Form A) of Formula I.

[0034] In another embodiment, the present disclosure provides one or more crystalline forms of 4(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB).

[0035] In another embodiment, one or more crystalline forms are Polymorphic Crystalline Forms 1, 2 and 3 (individually referred to herein as Form 1, Form 2 and Form 3, respectively) of Formula IB.

[0036] In another embodiment, the crystalline polymorph Form 1 of 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB) is a crystalline polymorphic hemihydrate form.

[0037] In another embodiment, Form 2 and Form 3 of crystalline polymorph of 4(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB) are anhydrous, solvent-free crystalline polymorphic forms. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 is a graph showing the combined biological efficacy in a greenhouse study against Septoria Leaf Blight caused by Zymoseptoria tritici.

[0039] Figure 2 is a graph showing the biological efficacy in a cross-analysis of replicated field trials in three geographic locations against Septoria Leaf Blight caused by Zymoseptoria tritici. Petition 870250102165, dated 07 / 11 / 2025, page 87 / 176 9 / 77

[0040] Figure 3 is a graph showing the biological efficacy in a cross-analysis of replicated field trials in three geographic locations against barley net blotch caused by Pyrenophora teres.

[0041] Figure 4 is a graph showing the biological efficacy in a cross-analysis of replicated field trials in three geographic locations against ramularia leaf spot in barley caused by Ramularia collo-cygni.

[0042] Figure 5 is a graph showing the biological efficacy in a cross-analysis of replicated field trials in three geographic locations against barley scald caused by Rhynchosporium secalis.

[0043] Figure 6 is a graph showing the biological efficacy in a cross-analysis of replicated field trials in three geographic locations against barley rust caused by Puccinia hordei.

[0044] Figure 7 shows an X-ray diffraction pattern of 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate powder (Formula I), Form A (solvent-free and anhydrous), as prepared in Example 12 of the present disclosure.

[0045] Figure 8 shows an X-ray diffraction pattern of 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride powder (Formula IB), Form 1 (hemihydrate), as prepared in Example 17 of the present disclosure.

[0046] Figure 9 shows an X-ray diffraction pattern of 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride powder (Formula IB), Form 2 (solvent-free and anhydrous), as prepared in Example 19 of the present disclosure. Petition 870250102165, dated 07 / 11 / 2025, page 88 / 176 10 / 77

[0047] Figure 10 shows an X-ray diffraction pattern of 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride powder (Formula IB, solvent-free and anhydrous), Form 3, as prepared in Example 24 of the present disclosure. DETAILED DESCRIPTION

[0048] The compounds of the present disclosure can be applied by any of a variety of known techniques, either as the compounds themselves or as formulations comprising the compounds. For example, the compounds can be applied to the roots or foliage of plants for the control of various fungi without damaging the commercial value of the plants. The materials can be applied in the form of any of the commonly used formulation types, for example, as solutions, dusts, wet powders, fluid concentrates or emulsifying concentrates.

[0049] Preferably, the compounds of the present disclosure are applied in the form of a formulation comprising one of the compounds of Formula I with a phytologically acceptable carrier. Concentrated formulations may be dispersed in water, or other liquids, for application, or formulations may be in powder or granular form, which may then be applied as is by the end user. The formulations may be prepared in accordance with procedures that are conventional in agricultural chemical technique.

[0050] The present disclosure covers all vehicles by which one of the compounds can be formulated for delivery and used as a fungicide. Typically, formulations are applied as aqueous suspensions or emulsions. Such suspensions or emulsions can be produced from water-soluble formulations, which can be suspended in Petition 870250102165, dated 07 / 11 / 2025, page 89 / 176 11 / 77 water or emulsifiers that are solids, commonly known as wet powders; or liquids, commonly known as emulsifying concentrates, aqueous suspensions or suspension concentrates. As will be readily verified, the compounds of the present disclosure can be added to any material, provided that the material produces the desired utility without significant interference with the activity of these compounds as antifungal agents.

[0051] Wet powders, which can be compacted to form water-dispersible granules, comprise an intimate mixture of one of the compounds of Formula I, an inert carrier, and optional additives such as surfactants. The concentration of the compound of Formula I in the wet powder can be from about 10 percent to about 90 percent by weight based on the total weight of the wet powder, more preferably from about 25 percent by weight to about 75 percent by weight. In the preparation of wet powder formulations, the compound of Formula I can be mixed with any finely divided solid carrier, such as pyrophyllite, talc, chalk, gypsum, Fuller's earth, bentonite, attapulgite, starch, casein, gluten, montmorillonite clays, diatomaceous earth, purified silicates, or the like. In such operations, the finely divided carrier and other optional additives are typically blended with the compound of Formula I and ground.

[0052] Emulsifiable concentrates comprise an active ingredient, such as the compounds of Formula I, dissolved in an inert carrier, which is a water-miscible solvent or a mixture of water-immiscible organic solvents and emulsifiers. Emulsifiable concentrates may comprise a convenient concentration, such as from about 1 percent by weight to about Petition 870250102165, dated 07 / 11 / 2025, pp. 90 / 176 12 / 77 percent by weight of the compound of Formula I, based on the total weight of the concentrate. Emulsifiable concentrates can be diluted with water to form spray mixtures in the form of oil-in-water emulsions. Other ingredients, including but not limited to surfactants, adjuvants, oils, antifoaming agents and stabilizers, may be added to the emulsifiable concentrate or may be mixed into the emulsifiable concentrate during dilution to form the spray mixture.

[0053] Emulsifiers that can be advantageously employed in the present document can be readily determined by those skilled in the art and include various nonionic, anionic, cationic, and amphoteric emulsifiers, or a mixture of two or more emulsifiers. Examples of nonionic emulsifiers useful in the preparation of emulsifying concentrates include polyalkylene glycol ethers and condensation products of alkyl and aryl phenols, aliphatic alcohols, aliphatic amines or fatty acids with ethylene oxide, propylene oxides, such as ethoxylated alkyl phenols and carboxylic esters solubilized with polyol or polyoxyalkylene. Cationic emulsifiers include quaternary ammonium compounds and fatty amine salts. Anionic emulsifiers include oil-soluble salts (e.g., calcium) of alkylaryl sulfonic acids, oil-soluble salts or sulfated polyglycol ethers, and appropriate salts of phosphated polyglycol ether.

[0054] Representative organic liquids that can be used in the preparation of emulsifying concentrates of the compounds of the present disclosure are aromatic liquids, such as xylene, propyl benzene fractions or fractions of Petition 870250102165, dated 07 / 11 / 2025, page 91 / 176 13 / 77 mixed naphthalene, substituted aromatic organic liquids, such as dioctyl phthalate; kerosene; dialkylamides of various fatty acids, particularly dimethylamides of fatty glycols and glycol derivatives, such as n-butyl ether, ethyl ether or methyl ether of diethylene glycol or methyl ether of triethylene glycol, petroleum fractions or hydrocarbons, such as mineral oil, aromatic solvents, paraffinic oils and the like; terpenic solvents, including rosin derivatives; aliphatic ketones, such as cyclohexanone; complex alcohols, such as 2-ethoxyethanol; Vegetable oils, such as soybean oil, rapeseed oil, olive oil, castor oil, sunflower seed oil, coconut oil, corn oil, cottonseed oil, linseed oil, palm oil, peanut oil, safflower oil, sesame oil, tung oil and the like; esters of the above and similar vegetable oils.Mixtures of two or more organic liquids can also be used in the preparation of the emulsifying concentrate. Organic liquids include xylene and propylbenzene fractions, with xylene being the preferred choice in some cases. Surface-active dispersing agents are typically used in liquid formulations in amounts ranging from 0.1 to 20 percent by weight based on the combined weight of the dispersing agent with one of the compounds. Formulations may also contain other compatible additives, for example, plant growth regulators and other biologically active compounds used in agriculture.

[0055] Aqueous suspensions comprise finely divided solids or powders of a water-insoluble active ingredient, such as a compound of Formula I, dispersed in an aqueous carrier at a concentration in the range of about 1 Petition 870250102165, dated 07 / 11 / 2025, page 92 / 176 14 / 77 at approximately 50 percent by weight, based on the total weight of the aqueous suspension. The suspensions are prepared by finely grinding the compound and vigorously mixing the ground material in a carrier containing water and surfactants chosen from the same types discussed above. Other components, such as inorganic salts and synthetic or natural gums, may also be added to increase the density and viscosity of the aqueous carrier.

[0056] The compounds of Formula I can also be applied as granular formulations, which are particularly useful for soil applications. Granular formulations generally contain from about 0.5 to about 10 percent by weight of the active ingredient, based on the total weight of the granular formulation, dispersed in an inert solid carrier consisting entirely or largely of coarsely divided inert material, such as attapulgite, bentonite, diatomite, clay, or a similar low-cost substance. Such formulations can be prepared by dissolving the compounds in a suitable solvent and applying them to the solid carrier which has been preformed to the appropriate particle size, for example, in the range of about 0.5 to about 3 millimeters (mm). A suitable solvent is a solvent in which the compound is substantially or completely soluble.Such formulations can also be prepared by making a paste or mass of the carrier and compound with a solvent and then grinding and drying the paste or mass to obtain the desired granular particle. Alternatively, such formulations can be prepared by making a paste or mass of the carrier and compound with a solvent and then extruding the paste or mass to form granules of the formulation. Petition 870250102165, dated 07 / 11 / 2025, p. 93 / 176 15 / 77

[0057] Dusts containing the compounds of Formula I can be prepared by intimately mixing one of the compounds in powder form with a suitable dusty agricultural carrier, such as, for example, kaolin clay, ground volcanic rock and the like. Dusts can suitably contain from about 1 to about 10 percent by weight of the compounds, based on the total weight of the dust.

[0058] The formulations may additionally contain adjuvant surfactants to enhance the deposition, wetting, and penetration of the compounds into the target crop and organism. These adjuvant surfactants may optionally be employed as a component of the formulation or as a tank mix. The amount of adjuvant surfactant will typically vary from 0.01 to 1.0 percent by volume, based on a volume of spray water, preferably from 0.05 to 0.5 percent by volume.Suitable adjuvant surfactants include, but are not limited to, ethoxylated nonyl phenols, ethoxylated synthetic or natural alcohols, salts or esters of sulfosuccinic acids, ethoxylated organosilicones, ethoxylated fatty amines, mixtures of surfactants with mineral or vegetable oils, culture oil concentrate (mineral oil (85%) + emulsifiers (15%)); nonylphenol ethoxylate; quaternary ammonium salt of benzyl cocoalkyldimethyl; mixture of petroleum hydrocarbon, alkyl esters, organic acid and anionic surfactant; C9-C11 alkyl polyglucoside; phosphate alcohol ethoxylate; natural primary alcohol ethoxylate (C12-C16); di-sec butylphenol EO-PO block copolymer; polysiloxane-methyl cap; Nonylphenol ethoxylate + urea ammonium nitrate; emulsified methylated seed oil; (synthetic) alcohol ethoxylate. Petition 870250102165, dated 07 / 11 / 2025, page 94 / 176 16 / 77 tridecyl (8EO); tallow amine ethoxylate (15 EO); PEG-99 dioleate (400). The formulations may also include oil-in-water emulsions, such as those disclosed in patent application serial number US 11 / 495,228, the disclosure of which is expressly incorporated herein by reference.

[0059] Another embodiment of the present disclosure is a method for controlling or preventing fungal attack. This method comprises applying to the soil, plant, roots, foliage or locus of the fungus, or to a locus where infestation should be prevented (for example, applying to cereal or grape plants), an effective amount as a fungicide of one of the compounds of Formula I. The compounds are suitable for treating various plants at fungicidal levels while exhibiting low phytotoxicity. The compounds can be useful in both a protective and an eradicative manner.

[0060] The compounds of Formula I have demonstrated significant fungicidal effect, particularly for agricultural use. Many of the compounds are particularly effective for use with agricultural crops and horticultural plants.

[0061] It will be understood by those skilled in the art that the effectiveness of the compound against the aforementioned fungi establishes the general usefulness of the compounds as fungicides.

[0062] The compounds of Formula I have broad ranges of activity against fungal pathogens. Exemplary pathogens may include, but are not limited to, the causative agent of wheat leaf septoria (Zymoseptoria tritici), brown spot of barley (Cochliobolus sativus), brown leaf rust of wheat (Puccinia triticina), yellow rust of wheat (Puccinia striiformis), common smut of Petition 870250102165, dated 07 / 11 / 2025, pp. 95 / 176 17 / 77 corn (Ustilago maydis), powdery mildew of grapevine (Uncinula necator), barley scald (Rhynchosporium secalis), rice blast (Magnaporthe oryzae), Asian soybean rust (Phakopsora pachyrhizi), wheat glume blotch (Parastagonospora nodorum), anthracnose of cucurbits (Colletotrichum orbiculare), barley rust (Puccinia hordei), cercospora leaf spot of beet (Cercospora beticola), tomato black spot (Alternaria solani), barley nettle blotch (Pyrenophora teres), wheat powdery mildew (Blumeria graminis f. sp. tritici), barley powdery mildew (Blumeria graminis f. sp.(hordei), cucurbit powdery mildew (Erysiphe cichoracearum), cucurbit powdery mildew (Podosphaera xanthii), root rot (Rhizoctonia solani), gray mold (Botrytis cinerea), ramularia leaf spot in barley (Ramularia collo-cygni), wheat yellow spot (Pyrenophora tritici-repentis), corn leaf blight (Exserohilum turcicum), corn polysora rust (Puccinia polysora), white mold (Sclerotinia sclerotiorum), soybean powdery mildew (Erysiphe diffusa), apple powdery mildew (Podosphaera leucotricha), soybean anthracnose (Colletotrichum truncatum), soybean leaf blight (Cercospora kikuchii), frog-eye leaf spot of soybean (Cercospora sojina), target spot of soybean (Corynespora cassiicola) and soybean brown spot (Septoria glycines).The exact amount of active ingredient to be applied depends not only on the specific active ingredient being used, but also on the particular action desired, the fungal species to be controlled and its growth stage, as well as the part of the plant or other product to be placed in contact with the active ingredient. Therefore, not all compounds, and the formulations containing them, may be equally effective at similar concentrations. Petition 870250102165, dated 07 / 11 / 2025, pp. 96 / 176 18 / 77 against the same fungal species.

[0063] The compounds of Formula I are effective when used on plants in a disease-inhibiting and phytologically acceptable amount. The terms “disease-inhibiting amount” or “phytologically acceptable amount” refer to an amount of a compound that kills or inhibits the plant disease whose control is desired, but is not significantly toxic to the plant. This amount will generally be from about 0.1 to about 1000 ppm (parts per million), where 1 to 500 ppm is preferred. The exact concentration of the compound required varies with the fungal disease to be controlled, the type of formulation employed, the method of application, the particular plant species, the climatic conditions, and the like. An adequate application rate is typically in the range of about 0.10 to about 4 pounds per acre (about 0.01 to 0.45 grams per square meter, g / m2).

[0064] The crystalline forms disclosed in this document can be prepared using various solvents and solvent mixtures from different classes of solvents, such as alcohols, ketones, esters, ethers, hydrocarbons, polar aprotic solvents, and water. For example, the crystalline Form A of Formula I can be prepared using ethyl acetate. For example, the crystalline Form 1 of Formula IB can be prepared using various different solvents, including, but not limited to, toluene, ethanol, isopropyl alcohol, dichloromethane, ethyl acetate, isopropyl acetate, methyl isobutyl ketone, methyl ethyl ketone, heptane, chloroform, acetonitrile, acetone, methyl tert-butyl ether, and mixtures thereof. For example, the crystalline Form 2 of Formula IB can be prepared using various solvents. Petition 870250102165, dated 07 / 11 / 2025, page 97 / 176 19 / 77 different solvents, including, but not limited to, isopropyl alcohol, methyl isobutyl ketone, methyl ethyl ketone, heptane, 2-methyl tetrahydrofuran, methyl tert-butyl ether, and mixtures thereof. For example, the crystalline Form 3 of Formula IB can be prepared using various different solvents, including, but not limited to, ethyl acetate, tetrahydrofuran, methyl isobutyl ketone, acetone, methyl tert-butyl ether, and mixtures thereof.

[0065] A unique physical form of 4(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate (Formula I), Polymorph Form A, was prepared according to the methods described in this document. The powder X-ray diffraction (PXRD) pattern of Polymorph Form A is shown in Figure 7, with corresponding tabulated data shown in Table A. Table A 2 theta (2Θ) (degrees) d-spacing (Â) Relative Peak Height (Irei) Intensity and Qualitative a* 5.54 15.9286 510.86 s 5.57 15.8421 95.07 vw 11.05 7.9998 95.84 vw 12.35 7.1599 847.35 vs 14.17 6.2462 493.22 m 15.14 5.8487 112.46 w 15.17 5.8371 43.27 vw 16.13 5.4889 104.96 w 16.68 5.3109 238.66 m 17.56 5.0473 58.39 vw Petition 870250102165, dated 07 / 11 / 2025, pp. 98 / 176 20 / 77 2 theta (2Θ) (degrees) d-spacing (Â) Relative Peak Height (Irei) Intensity and Qualitative a* 18.28 4.8485 4 6.66 vw 18.77 4.7245 407.71 m 19.22 4.6139 63.25 vw 19.55 4.5361 36.2 vw 20.58 4.3116 68.05 vw 21.28 4.1722 461.23 m 21.61 4.1086 681.2 s 21.88 4.0581 460.79 m 23.31 3.8136 1000 vs 23.34 3.8087 123.96 w 23.70 3.7512 216.43 m 24.34 3.6547 207.47 m 25.49 3.4923 37.24 vw 25, 91 3.4361 35.43 vw 26.76 3.3292 127.76w 27.12 3.2855 698.62s 28.18 3.1643 61.04 vw 28.87 3.0896 29.78 vw 31.02 2.8804 52.62 vw 31.30 2.8559 28.62 vw 33.02 2.7106 114.36w 34.29 2.613 36.53 vw * S = strong (>50% relative intensity), M = medium (20-50% relative intensity), W = weak (<20% relative intensity); V = very

[0066] In some embodiments, the Form A crystalline polymorph of Formula I has a ray diffraction pattern Petition 870250102165, dated 07 / 11 / 2025, page 99 / 176 21 / 77 X of powder comprising one or more peaks at diffraction angles (2θ) of 5.5 ± 0.2, 5.6 ± 0.2, 11.1 ± 0.2, 12.4 ± 0.2, 14.2 ± 0.2, 15.1 ± 0.2, 15.2 ± 0.2, 16.1 ± 0.2, 16.7 ± 0.2, 17.6 ± 0.2, 18.3 ± 0.2, 18.8 ± 0.2, 19.2 ± 0.2, 19.6 ± 0.2, 20.6 ± 0.2, 21.3 ± 0.2, 21.6 ± 0.2, 21.9 ± 0.2, 23.3 ± 0.2, 23.3 ± 0.2, 23.7 ± 0.2, 24.3 ± 0.2, 25.5 ± 0.2, 25.9 ± 0.2, 26.8 ± 0.2, 27.1 ± 0.2, 28.2 ± 0.2, 28.9 ± 0.2, 31.0 ± 0.2, 31.3 ± 0.2, 33.0 ± 0.2, and 34.3 ± 0.2.In some embodiments, the crystalline polymorph Form A of Formula I has a powder X-ray diffraction pattern comprising one or more peaks at diffraction angles (2θ) of 5.5 ± 0.1, 5.6 ± 0.1, 11.1 ± 0.1, 12.4 ± 0.1, 14.2 ± 0.1, 15.1 ± 0.1, 15.2 ± 0.1, 16.1 ± 0.1, 16.7 ± 0.1, 17.6 ± 0.1, 18.3 ± 0.1, 18.8 ± 0.1, 19.2 ± 0.1, 19.6 ± 0.1, 20.6 ± 0.1, 21.3 ± 0.1, 21.6 ± 0.1, 21.9 ± 0.1, 23.3 ± 0.1, 23.3 ± 0.1, 23.7 ± 0.1, 24.3 ± 0.1, 25.5 ± 0.1, 25.9 ± 0.1, 26.8 ± 0.1, 27.1 ± 0.1, 28.2 ± 0.1, 28.9 ± 0.1, 31.0 ± 0.1, 31.3 ± 0.1, 33.0 ± 0.1, and 34.3 ± 0.1. In some embodiments, the crystalline polymorph Form A of Formula I has a powder X-ray diffraction pattern comprising a combination of two or more peaks at diffraction angles (2θ) as given in the embodiments above. It will be appreciated that the diffraction angles (2θ) given in Table A are within the experimental error of the values ​​given above and also referred to in the present disclosure.

[0067] In a further embodiment, the crystalline polymorph Form A of Formula I has a powder X-ray diffraction pattern comprising a peak at the diffraction angle (2θ) of 23.3 ± 0.2. In a further embodiment, the crystalline polymorph Form A of Formula I has a powder X-ray diffraction pattern comprising peaks at angles of Petition 870250102165, dated 07 / 11 / 2025, pp. 100 / 176 22 / 77 diffraction (2θ) of 12.4 ± 0.2 and 23.3 ± 0.2. In a further embodiment, the crystalline polymorph Form A of Formula I has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2Θ) of 12.4 ± 0.2, 23.3 ± 0.2 and 27.1 ± 0.2. In a further embodiment, the crystalline polymorph Form A of Formula I has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2Θ) of 12.4 ± 0.2, 21.6 ± 0.2, 23.3 ± 0.2 and 27.1 ± 0.2. In a further embodiment, the crystalline polymorph Form A of Formula I has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2Θ) of 5.5 ± 0.2, 12.4 ± 0.2, 21.6 ± 0.2, 23.3 ± 0.2 and 27.1 ± 0.2.

[0068] In a further embodiment, the crystalline polymorph Form A of Formula I has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2Θ) essentially equal to those shown in Figure 7.

[0069] A unique physical form of 4(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB), Polymorph Form 1, was prepared according to the methods described in this document. The powder X-ray diffraction (PXRD) pattern of Polymorph Form 1 is shown in Figure 8, with corresponding tabulated data shown in Table B. Table B 2 theta (degrees) (2Θ) d- spacing (Â) Relative Height Peak (Irei) of Intensity Qualitative iva* 6, 91 12,7903 191,88 w 9, 42 9, 384 59, 4 vw Petition 870250102165, dated 07 / 11 / 2025, pp. 101 / 176 23 / 77 2 theta (2Θ) (degrees) d- spacing (Â) Relative Peak Height (Irei) Quality Intensity iva* 6.4237 117.21 w 15.08 5.872 247.76 m 15.77 5.6144 61.99 wv 16.89 5.2447 132.5 w 18.01 4.9211 35.19.9 ww 4.716 429.15 m 20.61 4.3054 68.54 vw 21.13 4.2017 45.63 vw 21.85 4.0637 274.81 m 23.03 3.8581 269.9 m 23.58 vs 3.702 24.76 3.5931 32.77 vw 25.33 3.5128 121.41 w 25.91 3.4361 323.91 m 26.70 3.3366 257.7 m 27.36 3.256 18.2.2 938 w 3.0833 89.55 vw 29.69 3.0064 34.28 vw 30.27 2.9506 94.86 vw 30.78 2.9025 71.77 vw 31.60 2.8293 81.33 vw 2.66 53 vw * S = strong (>50 % of relative intensity), Μ = medium (20–50 % of relative intensity), W = weak (<20 % of Petition 870250102165, of 07 / 11 / 2025, p. 102 / 176 24 / 77 relative intensity); V = memory

[0070] In some embodiments, the crystalline polymorph Form 1 of Formula IB has a powder X-ray diffraction pattern comprising one or more peaks at diffraction angles (2θ) of 6.9 ± 0.2, 9.4 ± 0.2, 10.5 ± 0.2, 12.1 ± 0.2, 12.6 ± 0.2, 13.8 ± 0.2, 15.1 ± 0.2, 15.8 ± 0.2, 16.9 ± 0.2, 18.0 ± 0.2, 18.7 ± 0.2, 20.6 ± 0.2, 21.1 ± 0.2, 21.9 ± 0.2, 23.0 ± 0.2, 23.6 ± 0.2, 24.8 ± 0.2, 25.3 ± 0.2, 25.9 ± 0.2, 26.7 ± 0.2, 27.4 ± 0.2, 28.9 ± 0.2, 29.7 ± 0.2, 30.3 ± 0.2, 30.8 ± 0.2, 31.6 ± 0.2, and 33.8 ± 0.2.In some embodiments, the Form 1 crystalline polymorph of Formula IB has a powder X-ray diffraction pattern comprising one or more peaks at diffraction angles (2θ) of 6.9 ± 0.1, 9.4 ± 0.1, 10.5 ± 0.1, 12.1 ± 0.1, 12.6 ± 0.1, 13.8 ± 0.1, 15.1 ± 0.1, 15.8 ± 0.1, 16.9 ± 0.1, 18.0 ± 0.1, 18.7 ± 0.1, 20.6 ± 0.1, 21.1 ± 0.1, 21.9 ± 0.1, 23.0 ± 0.1, 23.6 ± 0.1, 24.8 ± 0.1, 25.3 ± 0.1, 25.9 ± 0.1, 26.7 ± 0.1, 27.4 ± 0.1, 28.9 ± 0.1, 29.7 ± 0.1, 30.3 ± 0.1, 30.8 ± 0.1, 31.6 ± 0.1, and 33.8 ± 0.1. In some embodiments, the Form 1 crystalline polymorph of Formula IB has a powder X-ray diffraction pattern comprising a combination of two or more peaks at diffraction angles (2θ) as given in the embodiments above. It will be appreciated that the diffraction angles (2θ) given in Table B are within the experimental error of the values ​​given above and also referred to in the present disclosure.

[0071] In a further embodiment, the crystalline polymorph Form 1 of Formula IB has a powder X-ray diffraction pattern comprising a peak at the diffraction angle (2θ) of 23.6 ± 0.2. In a further embodiment, the crystalline polymorph Form 1 of Formula IB has a pattern of Petition 870250102165, dated 07 / 11 / 2025, pp. 103 / 176 25 / 77 X-ray powder diffraction comprising peaks at diffraction angles (2Θ) of 12.1 ± 0.2 and 23.6 ± 0.2. In a further embodiment, the crystalline polymorph Form 1 of Formula IB has an X-ray powder diffraction pattern comprising peaks at diffraction angles (2Θ) of 12.1 ± 0.2, 18.7 ± 0.2 and 23.6 ± 0.2. In a further embodiment, the crystalline polymorph Form 1 of Formula IB has an X-ray powder diffraction pattern comprising peaks at diffraction angles (2Θ) of 10.5 ± 0.2, 12.1 ± 0.2, 18.7 ± 0.2 and 23.6 ± 0.2. In a further embodiment, the Formula IB crystalline polymorph Form 1 has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2Θ) of 10.5 ± 0.2, 12.1 ± 0.2, 18.7 ± 0.2, 23.6 ± 0.2 and 25.9 ± 0.2.

[0072] In a further embodiment, the Form 1 crystalline polymorph of Formula IB has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2Θ) essentially equal to those shown in Figure 8.

[0073] A unique physical form of 4(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB), Polymorph Form 2, was prepared according to the methods described in this document. The powder X-ray diffraction (PXRD) pattern of Polymorph Form 2 is shown in Figure 9, with corresponding tabulated data shown in Table C. Table C 2 theta (2Θ) (degrees) d-spacing (Â) Relative Peak Height (Irei) Qualitative Intensity a* 4.88 18.1008 496.56 m Petition 870250102165, dated 07 / 11 / 2025, pp. 104 / 176 OH / OH 2 tits (2θ) (coarse) d-spacing (Â) Relative Peak Height (Irei) Intensity and Qualitativ a* 9.60 9.2069 1000 vs 12.23 7.2305 70.21 vw 12.84 6.8909 180.56 w 12.87 6.8748 32.38 vw 13.44 6.582 176.74 w 14.32 6.1805 150.32 w 14.86 5.9552 245.3 m 14.89 5.9432 49.78 vw 16.10 5.4991 345.88 m 17.01 5.2077 123.8 w 17.50 5.0647 128.13 w 18.13 4.8886 334.84 m 19.04 4.6575 73.25 vw 20.28 4.3753 287.25 m 20.13. 92 4.2438 160.89 w 21.58 4.1143 642.8 s 21.61 4.1086 95.24 vw 22.55 3.9398 131.06 w 23.31 3.8136 123.27 w 23.82 3.7324 79, 83 vw 24.52 3,628 453.78 m 25.09 3.5462 99, 54 vw 25, 94 3.4322 38.33 vw 27.00 3.2999 103.72 w 27.42 3.2499 44.29 vw 28, 63 3.1152 87.17 vw Petition 870250102165, dated 07 / 11 / 2025, p. 105 / 1 27 / 7 2 teta (2Θ) (coarse) d-spacing (Â) Relative Peak Height (Irei) Intensity and Qualitativ a* 29.42 3.0337 124.28 w 29.69 3.0064 77.8 vw 30.42 2.9363 34.36 vw 60 2.8293 83 vw 33.72 2.6562 41.02 vw 38.41 2.3419 45.94 vw * S = strong (>50% relative intensity), M = medium (20-50% relative intensity), W = weak (<20% relative intensity); V = very

[0074] In some embodiments, the crystalline polymorph Form 2 of Formula IB has a powder X-ray diffraction pattern comprising one or more peaks at diffraction angles (2Θ) of 4.9 ± 0.2, 9.6 ± 0.2, 12.2 ± 0.2, 12.8 ± 0.2, 12.9 ± 0.2, 13.4 ± 0.2, 14.3 ± 0.2, 14.9 ± 0.2, 14.9 ± 0.2, 16.1 ± 0.2, 17.0 ± 0.2, 17.5 ± 0.2, 18.1 ± 0.2, 19.0 ± 0.2, 20.3 ± 0.2, 20.9 ± 0.2, 21.6 ± 0.2, 21.6 ± 0.2, 22.6 ± 0.2, 23.3 ± 0.2, 23.8 ± 0.2, 24.5 ± 0.2, 25.1 ± 0.2, 25.9 ± 0.2, 27.0 ± 0.2, 27.4 ± 0.2, 28.6 ± 0.2, 29.4 ± 0.2, 30.4 ± 0.2, 31.6 ± 0.2, 33.7 ± 0.2, and 38.4 ± 0.2.In some embodiments, the crystalline polymorph Form 2 of Formula IB has a powder X-ray diffraction pattern comprising one or more peaks at diffraction angles (2Θ) of 4.9 ± 0.1, 9.6 ± 0.1, 12.2 ± 0.1, 12.8 ± 0.1, 12.9 ± 0.1, 13.4 ± 0.1, 14.3 ± 0.1, 14.9 ± 0.1, 14.9 ± 0.1, 16.1 ± 0.1, 17.0 ± 0.1, 17.5 ± 0.1, 18.1 ± 0.1, 19.0 ± 0.1, 20.3 ± 0.1, 20.9 ± 0.1, 21.6 ± 0.1, 21.6 ± 0.1, 22.6 ± 0.1, 23.3 ± 0.1, 23.8 ± 0.1, 24.5 ± 0.1, 25.1 ± 0.1, 25.9 ± 0.1, 27.0 ± 0.1, 27.4 ± 0.1, 28.6 ±. Petition 870250102165, dated 07 / 11 / 2025, pp. 106 / 176 28 / 77 0.1, 29.4 ± 0.1, 30.4 ± 0.1, 31.6 ± 0.1, 33.7 ± 0.1, and 38.4 ± 0.1. In some embodiments, the Form 2 crystalline polymorph of Formula IB has a powder X-ray diffraction pattern comprising a combination of two or more peaks at diffraction angles (2θ) as given in the embodiments above. It will be appreciated that the diffraction angles (2θ) given in Table C are within the experimental error of the values ​​given above and also referred to in the present disclosure.

[0075] In a further embodiment, the crystalline polymorph Form 2 of Formula IB has a powder X-ray diffraction pattern comprising a peak at diffraction angle (2θ) of 9.6 ± 0.2. In a further embodiment, the crystalline polymorph Form 2 of Formula IB has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 9.6 ± 0.2 and 21.6 ± 0.2. In a further embodiment, the crystalline polymorph Form 2 of Formula IB has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 4.9 ± 0.2, 9.6 ± 0.2 and 21.6 ± 0.2. In a further embodiment, the Formula IB crystalline polymorph Form 2 has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 4.9 ± 0.2, 9.6 ± 0.2, 21.6 ± 0.2 and 24.5 ± 0.2.In a further embodiment, the Formula IB crystalline polymorph Form 2 has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 4.9 ± 0.2, 9.6 ± 0.2, 16.1 ± 0.2, 21.6 ± 0.2 and 24.5 ± 0.2.

[0076] In a further embodiment, the Form 2 crystalline polymorph of Formula IB has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) essentially equal to those shown in Figure 9. Petition 870250102165, dated 07 / 11 / 2025, pp. 107 / 176 29 / 77

[0077] A unique physical form of 4(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB), Polymorph Form 3, was prepared according to the methods described in this document. The powder X-ray diffraction (PXRD) pattern of Polymorph Form 3 is shown in Figure 10, with corresponding tabulated data shown in Table D. Table D 2 theta (2Θ) (degrees) d-spacing (Â) Relative Peak Height (Irei) Intensity and Qualitative a* 4.67 18.922 694.44 s 4.70 18.8001 216.98 m 9.36 9.4445 1000 vs 12.84 6.8909 137.53 w 12.87 6.8748 31.82 vw 13.47 6.5673 90.13 vw 14.05 6.2997 94.5 vw 14.44 6.129 144.21 w 15.80 5.6038 19.81 vw 16.50 5.3689 186.48w 17.22 5.1441 175.59w 17.89 4.9542 24.35 vw 18.95 4.6796 369.6m 20.25 4.3817 45.97 vw 21.10 4.2076 333.2 m 22.28 3.9873 99.36 vw 22.67 3.919 113.55 w 23.34 3.8087 87.07 vw Petition 870250102165, dated 07 / 11 / 2025, pp. 108 / 176 30 / 77 2 theta (2Θ) (degrees) d-spacing (Â) Relative Peak Height (Irei) Intensity and Qualitative a* 24.67 3.6061 352.35 m 25.12 3.5419 186.85 w 25.67 3.468 4 6.26 vw 26.85 3.3182 72.47 vw 27.36 3.2569 81.57 vw 28.03 3.1811 104.52 w 29.18 3.0583 46.73 vw 29.78 2.9975 47.66 vw 30.24 2.9535 28.86 vw 30.81 2.8997 40.57 vw 33.38 2.6819 24.32 vw 34.35 2.6085 20.26 vw 37.23 2.4134 32.87 vw 38.07 2.3616 34.64 vw 38.41 2.3419 21.54 vw * S = strong (>50% relative intensity), M = medium (20-50% relative intensity), W = weak (<20% relative intensity); V = very

[0078] In some embodiments, the crystalline polymorph Form 3 of Formula IB has a ray diffraction pattern X powder that (2Θ) of 4.7 0.2, 13.5 ± 0.2, 17.2 ± 0.2, 22.3 ± 0.2, 25.7 ± 0.2, 29.8 ± comprises u: ± 0.2, 4.7 0.2, 14.1 ± 0.2, 17.9 ± 0.2, 22.7 ± 0.2, 26.9 ± 0.2, 30.2 ± or more pic 0.2, 9.4 ± 0.2, 14.4 ± 0.2, 19.0 ± 0.2, 23.3 ± 0.2, 27.4 ± 0.2, 30.8 ± s in angles 0.2, 12.8 ± 0.2, 15.8 ± 0.2, 20.3 ± 0.2, 24.7 ± 0.2, 28.0 ± 0.2, 33.4 ± diffraction 0.2, 12.9 ± 0.2, 16.5 ± 0.2, 21.1 ± 0.2, 25.1 ± 0.2, 29.2 ± 0.2, 34.4 ± Petition 870250102165, dated 07 / 11 / 2025, pp. 109 / 176 31 / 77 0.2, 37.2 ± 0.2, 38.1 ± 0.2, and 38.4 ± 0.2. In some embodiments, the Form 3 crystalline polymorph IB has a powder X-ray diffraction pattern that has one or more peaks at diffraction angles (2θ) of 4.7 ± 0.1 14.1 ± 0.1 17.9 ± 0.1 22.7 ± 0.1 26.9 ± 0.1 30.2 ± 0.1 38.1 ± 0.1 9.4 ± 0.1 14.4 ± 0.1 19.0 ± 0.1 23.3 ± 0.1 27.4 ± 0.1 30.8 ± 0.1, and 38.4 ± 0.1. 12.8 ± 0.1 15.8 ± 0.1 20.3 ± 0.1 24.7 ± 0.1 28.0 ± 0.1 33.4 ± 0.1 12.9 ± 0.1 16.5 ± 0.1 21.1 ± 0.1 25.1 ± 0.1 29.2 ± 0.1 34.4 ± 0.1, of the formula comprises 4.7 ± 0.1, 13.5 ± 0.1, 17.2 ± 0.1, 22.3 ± 0.1, 25.7 ± 0.1, 29.8 ± 0.1, 37.2 ± 0.1, In some embodiments, the crystalline polymorph form of Formula IB has a powder X-ray diffraction pattern comprising a combination of two or more peaks at diffraction angles (2θ) as given in the embodiments above. It will be appreciated that the diffraction angles (2θ) given in Table D are within the experimental error of the values ​​given above and also referred to in the present disclosure.

[0079] In a further embodiment, the crystalline polymorph Form 3 of Formula IB has a powder X-ray diffraction pattern comprising a peak at diffraction angle (2θ) of 9.4 ± 0.2. In a further embodiment, the crystalline polymorph Form of Formula IB has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 4.7 ± 0.2 and 9.4 ± 0.2. In a further embodiment, the crystalline polymorph Form 3 of Formula IB has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 4.7 ± 0.2, 9.4 ± 0.2 and 19.0 ± 0.2. In a further embodiment, the Formula IB polymorph crystalline Form 3 has a powder X-ray diffraction pattern comprising peaks at diffraction angles. Petition 870250102165, dated 07 / 11 / 2025, pp. 110 / 176 32 / 77 (2θ) of 4.7 ± 0.2, 9.4 ± 0.2, 19.0 ± 0.2 and 24.7 ± 0.2. In a further embodiment, the crystalline polymorph Form 3 of Formula IB has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 4.7 ± 0.2, 9.4 ± 0.2, 19.0 ± 0.2, 21.1 ± 0.2 and 24.7 ± 0.2.

[0080] In a further embodiment, the crystalline polymorph Form 3 of Formula IB has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) essentially equal to those shown in Figure 10.

[0081] Any desired range or value given in this document may be extended or altered without losing the intended effects, as will be apparent to a person versed in understanding the teachings in this document.

[0082] The compounds of Formula I can be produced using well-known chemical procedures. Intermediates not specifically mentioned in this disclosure are commercially available, can be produced by routes disclosed in the chemical literature, or can be readily synthesized from commercial starting materials using standard procedures.

[0083] The following examples better illustrate Formula I compounds within the disclosure, but they should certainly not be interpreted as limiting their scope in any way.

[0084] Starting materials, reagents, and solvents that were obtained from commercial sources were used without further purification. Anhydrous solvents were purchased, such as Sure / Seal™ from Aldrich, and were used as received. Melting points were obtained on an OptiMelt Automated Melting Point System from Stanford Research Systems and were not corrected. The molecules were named Petition 870250102165, dated 07 / 11 / 2025, p. 111 / 176 33 / 77 according to the ChemDraw program (version 22.2.0.3300). If such a program is unable to name a molecule, that molecule has been named using conventional nomenclature rules. 1H NMR spectral data are in ppm (δ) and were recorded at 396, 400, and 500 MHz; 19F NMR spectral data are in ppm (δ) and were recorded at 376 or 471 MHz; and 31P NMR spectral data are in ppm (δ) and were recorded at 202 MHz, unless otherwise indicated. EXAMPLES AND METHODS Example 1: Preparation of 4-(difluoromethoxy)benzyl 4-amino-2,5-dimethylbenzoate CH3ch ro, - NH2ro., nh:'' H - ro CH3o ch

[0085] In a 20 milliliter (mL) flask, (4(difluoromethoxy)phenyl)methanol (253 milligrams (mg), 1.45 millimoles (mmol)), 4-amino-2,5-dimethylbenzoic acid (200 mg, 1.21 mmol) and 4-dimethylaminopyridine (DMAP, 14.8 mg, 0.121 mmol) were dissolved in dichloromethane (DCM, 6.05 mL) and the mixture was cooled to 0 °C in an ice / water bath. After approximately 5 minutes, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC, 279 mg, 1.45 mmol) was added in a portion and the resulting pale yellow reaction mixture was stirred overnight, slowly warming to room temperature as the ice melted. After 18 hours, thin-layer chromatography (TLC) indicated the consumption of the initial material. The reaction mixture was concentrated to produce an oil. The resulting material was purified by flash column chromatography (silica gel (SiO2), 0 to 100% ethyl acetate in Petition 870250102165, dated 07 / 11 / 2025, pp. 112 / 176 34 / 77 hexane) to produce the title compound (255 mg, 0.794 mmol, 66% yield) as a transparent colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.73 (s, 1H), 7.43 — 7.38 (m, 2H), 7.11 - 7.07 (m, 2H), 6.49 (t, J = 73.9 Hz, 1H), 6.42 (s, 1H), 5.24 (s, 2H), 3.94 (s, 2H), 2.50 (s, 3H), 2.08 (s, 3H);19F NMR (471 MHz, CDCl3) δ -80, 68 (d, J = 73.8 Hz); ESIMS m / z 322 ( [M+H]+). Example 2: Preparation of 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate nh2o ch3

[0086] In a 20 mL bottle, 4-(difluoromethoxy)benzyl 4-amino-2,5-dimethylbenzoate (239 mg, 0.744 mmol) was dissolved in trimethyl orthoformate (2 mL), and then p-toluenesulfonic acid monohydrate (14.2 mg, 0.074 mmol) was added. The reaction mixture was heated under reflux (100 °C) and stirred for 3 hours. After 3 hours, TLC indicated almost complete consumption of the initial material. The reaction was rapidly cooled with saturated aqueous sodium bicarbonate (NaHCO3, 10 mL), and the mixture was extracted with DCM (3 x 10 mL). The combined organic phases were passed through a phase separator and concentrated to a pale yellow oil. The residue was dissolved in DCM (0.5 mL), and N-ethyl-N-methylamine (66.0 mg, 1.12 mmol) was added dropwise using a syringe. The solution was heated to 40 °C and stirred for 3 hours. The reaction was rapidly cooled with water (10 mL) and the mixture was extracted with DCM (3 x 10 mL). The combined organic phases were passed through a phase separator and concentrated.The resulting material was purified by flash column chromatography (reversed phase). Petition 870250102165, dated 07 / 11 / 2025, pp. 113 / 176 35 / 77 C18, 30 to 100% acetonitrile in water) to produce the titrant compound (230 mg, 0.589 mmol, 79% yield) as a clear, colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.78 (s, 1H), 7.51 - 7.46 (m, 1H), 7.46 - 7.42 (m, 2H), 7.14 - 7.08 (m, 2H), 6.57 (s, 1H), 6.50 (t, J = 73.9 Hz, 1H), 5.27 (s, 2H), 3.57 - 3.24 (m, 2H), 3.00 (s, 3H), 2.55 (s, 3H), 2.23 (s, 3H), 1.20 (t, J = 7.2 Hz, 3H);19F NMR (471 MHz, CDCl3) δ -80.73 (d, J = 73.7 Hz); ESIMS m / z391 ([M+H])+). Example 3: Preparation of 4-(difluoromethoxy)benzyl4-((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride CH3 CH3 ch3ch KO - : ^NN CH3 KQ .?NN CH3— 'HC O ch3o ch

[0087] In a 25 mL flask, a solution of 4(difluoromethoxy)benzyl4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate (230 mg, 0.589 mmol) was prepared in DCM (2.95 mL). Hydrochloric acid (147 microliters (µL), 0.589 mmol, 4.0 M dioxane solution) was added in portions, and the resulting clear, colorless solution was stirred at room temperature for 4 hours. Volatiles were removed under reduced pressure to produce a colorless film. Methyl tert-butyl ether (5 mL) was added, and the resulting mixture was stirred vigorously. The titrant compound (133 mg, 0.341 mmol, 58% yield) was isolated by vacuum filtration as a white solid and as a mixture of isomers: 1H NMR (400 MHz, DMSO-d6) δ 11.18 - 10.79 (m, 1H), 8.54 - 8.27 (m, 1H), 7.79 (s, 1H), 7.55 (d, J = 8.2 Hz, 2H), 7.38 - 7.33 (m, 1H), 7.26 (t, J = 74.1 Hz, 1H), 7.22 (d, J = 8.2 Hz, 2H), 5.32 Petition 870250102165, dated 07 / 11 / 2025, pp. 114 / 176 36 / 77 (s, 2H), 3.75 — 3.61 (m, 2H), 3.32 - 3.25 (m, 3H), 2.52 2.49 (m, 3H), 2.38 - 2.32 (m, 3H), 1.30 - 1.23 (m, 3H) (~2:1 E:Z ratio isomers);19F NMR (376 MHz, DMSO-d6) δ -82.14; mp 95-100°C. Example 4: Preparation of 4-(dffluoromethoxy)benzyl4-((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride CH3 ch3ch F^O^^ Jt^N^F.0.· t. N^ ^ F . * F -HCl CH30 ch

[0088] The titrant compound can also be prepared as follows. A 500 mL jacketed reactor was equipped A CH3 reactor with a nitrogen inlet, temperature probe, stirrer, and outlet coupled to a scrubber was used. The reaction was loaded with N-ethyl-N-methylformamide (8.83 g, 97.4 mmol, 96.0 wt%) and anhydrous DCM (130 mL). The jacket was set to 20 °C and the mixture was stirred at 250 revolutions per minute (rpm). Oxalyl chloride (8.17 mL, 93.4 mmol) was added over 30 minutes. The mixture was stirred for one more hour after complete addition. 4-(difluoromethoxy)benzyl 4-amino-2,5-dimethylbenzoate (25.0 g, 77.8 mmol) was added as a solution in DCM (64.8 mL) over 90 minutes. The mixture was stirred for one more hour after complete addition. After 1 hour, the reaction was sampled and analyzed by HPLC, showing high conversion of the initial material. The reaction mixture was collected from the reactor and diluted with DCM (100 mL). The mixture was concentrated to approximately 1 / 2 of its volume; heptane (100 mL) was added and the mixture was concentrated to dryness.Complete overnight drying under vacuum yielded the titular compound (31.2 g, 73.1 mmol, 94% yield) as a whitish solid and as a mixture of isomers. Petition 870250102165, dated 07 / 11 / 2025, pp. 115 / 176 37 / 77 Example 5: Preparation of 4-(difluoromethoxy)benzyl 4-amino-2,5-dimethylbenzoate CH3CH3 F^O^·.. F^O.^\ í XXc ho^Çi T . O ch3o ch3

[0089] A solution of 4-amino-2,5-dimethylbenzoic acid (0.750 g, 4.54 mmol) was prepared in anhydrous N,N-dimethylformamide (DMF, 5.00 mL) in a magnetically shaken 20 mL flask. Potassium carbonate (0.816 g, 5.90 mmol) was added in portions at room temperature. The mixture was stirred for approximately 10 minutes. 1-(chloromethyl)4-(difluoromethoxy)benzene (0.874 g, 4.54 mmol) was added dropwise over approximately 5 minutes, and the resulting amber mixture was stirred at room temperature overnight. Ultra-high performance liquid chromatography (UPLC) analysis indicated near-complete consumption of the initial material. The reaction mixture was poured into water (25 mL) and extracted with diethyl ether (4 x 5 mL). The combined organic extracts were washed with water (5 x 20 mL) and brine (20 mL), dried over sodium sulfate, filtered, and concentrated to produce a wine-colored oil.Purification by flash column chromatography (reversed phase C18, 20 to 100% acetonitrile in water) yielded the titrant compound (1.05 g, 3.28 mmol, 72% yield) as a whitish solid. Example 6: Preparation of 4(difluoromethoxy)benzyl)-4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate phosphate Petition 870250102165, dated 07 / 11 / 2025, pp. 116 / 176 38 / 77 CH3 CH3 ch3ch3 FO .^ - N^ N CIF FO. .N-.NOF-'O.^- ” F <!--?.O.^H3PO4<br--> CH3O ch3

[0090] In a 40 mL flask fitted with a magnetic stir bar, a solution of 4-(difluoromethoxy)benzyl 4-(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate (200 mg, 0.512 mmol) was prepared in dry acetonitrile (1 mL). In a separate 4 mL flask, phosphoric acid (55.2 mg, 0.563 mmol) was dissolved in dry acetonitrile (1 mL) and this solution was added dropwise by syringe to the initial material solution. The resulting solution was stirred at room temperature for 15 minutes. The solvent was removed under reduced pressure and a light yellow solid was obtained. The solid was dried under high vacuum and triturated with dry diethyl ether (2 mL).The solvent was decanted (x3) to yield the titrant compound (220 mg, 0.450 mmol, 88% yield) as a white solid and as a mixture of isomers: 1H NMR (500 MHz, Acetone-d6) δ 8.10 - 7.87 (m, 1H), 7.77 (s, 1H), 7.61 - 7.53 (m, 2H), 7.25 - 7.18 (m, 2H), 7.17 - 6.80 (m, 2H), 5.31 (s, 2H), 3.73 - 3.57 (m, 2H), 3.26 (d, J = 6.5 Hz, 3H), 2.51 (s, 3H), 2.29 (d, J = 11.5 Hz, 3H), 1.29 (q, J = 8.4 Hz, 3H);19F NMR (471 MHz, Acetone-d 6) δ -82.72;31P NMR (202 MHz, Acetone-d 6) δ 1.80. Example 7: Preparation of 4(dl-fluoromethoxy)benzyl fumarate 4 (((etfl (metfl)amfno)metfleno)amfno)-2,5-df-metflbenzoate CH3 CH3 FONN CH31 Ov? - O ch3

[0091] A solution of CH3 CH3 FONN CH3 - Ci.-,ç 0. O ch3 Π oh O e 4-(difluoromethoxy)benzyl 4- Petition 870250102165, dated 07 / 11 / 2025, pp. 117 / 176 39 / 77 (((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate (200 mg, 0.512 mmol) was prepared in methanol (2 mL) in a 20 mL flask fitted with a magnetic stir bar. Fumaric acid (59.5 mg, 0.512 mmol) was added to this solution and the resulting solution was stirred at room temperature for 15 minutes. The solvent was removed under reduced pressure and the resulting oil was dried under high vacuum to produce a foamy solid, which was triturated with dry diethyl ether (2 mL). The solvent was decanted (x3) to produce the titrant compound (132 mg, 0.261 mmol, 51% yield) as a white solid and as a mixture of isomers: 1H NMR (500 MHz, CD3OD) δ 8.16 — 7.90 (m, 1H), 7.81 (s, 1H), 7.54 — 7.46 (m, 2H), 7.20 — 7.12 (m, 2H), 7.05 (s, 1H), 6.99 — 6.64 (m, 3H), 5.31 (s, 2H), 3.60 (q, J = 7.2 Hz, 2H), 3.25 — 3.15 (m, 3H), 2.54 (s, 3H), 2.30 (s, 3H), 1.31 (dt, J = 13.1, 7.3 Hz, 3H), in COO(H);19F NMR (471 MHz, CD3OD) δ 83.43. Example 8: Preparation of 4-(difluoromethoxy)benzyl oxalate 4-((-ethyl-methyl)amino)methylene)amino)-2,5-dimethylbenzoate CH3 N CH3 CH3

[0092] A solution of 4-(difluoromethoxy)benzyl 4-(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate (215 mg, 0.551 mmol) was prepared in DCM (2.75 mL) in a 5 mL flask equipped with a magnetic stir bar. Oxalic acid (49.6 mg, 0.551 mmol) was added to this clear, colorless solution, and the resulting solution was stirred at room temperature for 3 hours. The solvent was then removed. Petition 870250102165, dated 07 / 11 / 2025, pp. 118 / 176 40 / 77 under a stream of nitrogen. Dry diethyl ether (2 mL) was added and the flask was shaken to give a white solid precipitate which was collected by vacuum filtration. The titrant compound (185 mg, 0.385 mmol, 70% yield) was isolated as a white solid and as a mixture of isomers: 1H NMR (396 MHz, DMSO-d6) δ 7.93 (d, J = 65.1 Hz, 1H), 7.70 (s, 1H), 7.62 - 7.39 (m, 2H), 7.35 - 7.02 (m, 3H), 6.90 (d, J = 24.7 Hz, 1H), 5.27 (s, 2H), 3.47 (dq, J = 13.9, 6.8 Hz, 2H), 3.06 (d, J = 22.6 Hz, 3H), 2.47 (s, 3H), 2.20 (m, 3H), 1.18 (q, J = 5.7 Hz, 3H), in COO(H);19F NMR (471 MHz, DMSO- d 6) δ -82.03 (d, J = 73.8 Hz); mp 102-106°C. Example 9: Preparation of 4-(difluoromethyl)benzyl 4-(( ^etz:yl (methyl) amino)methylene) amino) 2,5-dimethylbenzoate tartrate N ' h CH3 NN CH3 OH O OH

[0093] A solution of 4-(difluoromethoxy)benzyl 4-(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate (200 mg, 0.512 mmol) was prepared in methanol (2 mL) in a 20 mL flask fitted with a magnetic stir bar. Tartaric acid (77.0 mg, 0.512 mmol) was added to this solution and the resulting solution was stirred at room temperature for 15 minutes. The solvent was removed under reduced pressure and the resulting oil was dried under high vacuum to produce a foamy brown solid, which was triturated with dry diethyl ether (2 mL). The solvent was decanted (x3) to produce the titrant compound (238 mg, 0.440 mmol, 86% yield) as a white solid and as a mixture of isomers: 1H NMR (500 MHz, CD3OD) δ 8.19 - 7.98 (m, 1H), Petition 870250102165, dated 07 / 11 / 2025, pp. 119 / 176 41 / 77 7.82 (s, 1H), 7.55 — 7.44 (m, 2H), 7.20 - 7.13 (m, 2H), 7.13 - 7.08 (m, 1H), 6.83 (t, J = 74.1 Hz, 1H), 5.32 (s, 2H), 4.42 (s, 2H), 3.63 (q, J = 7.2 Hz, 2H), 3.32 - 3.19 (m, 3H), 2.55 (s, 3H), 2.32 (s, 3H), 1.34 (t, J = 7.1 Hz, 3H), no O(H) or COO(H); mp 147 °C. Example 10: Preparation of 4-(difluorometoxi)benzil 4(((etil (metil)amino)metileno)amino)-2,5-dimetilbenzoato 4hidroxibenzoato

[0094] A solution of 4-(difluoromethoxy)benzyl 4-(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate (200 mg, 0.512 mmol) was prepared in methanol (2 mL) in a 20 mL flask fitted with a magnetic stir bar. To this solution was added 4-hydroxybenzoic acid (70.8 mg, 0.512 mmol) and the resulting solution was stirred at room temperature for 15 minutes. The solvent was removed under reduced pressure. The resulting brown oil was dried under high vacuum to produce a foamy brown solid, which was triturated with dry diethyl ether (2 mL).The solvent was decanted (x3) to produce the titrant compound (235 mg, 0.445 mmol, 87% yield) as a light brown solid and as a mixture of isomers: 1H NMR (500 MHz, CD3OD) δ 7.90 - 7.83 (m, 2H), 7.74 (s, 2H), 7.53 - 7.44 (m, 2H), 7.19 - 7.12 (m, 2H), 7.02 - 6.62 (m, 4H), 5.28 (s, 2H), 3.56 - 3.37 (m, 2H), 3.05 (s, 3H), 2.51 (s, 3H), 2.22 (s, 3H), 1.24 (t, J = 7.2 Hz, 3H), without -O(H) or COO(H);19F NMR (471 MHz, CD3OD) δ -83.34; mp 64°C. Example 11: Preparation of 4-(difluoromethoxy)benzyl succinate. Petition 870250102165, dated 07 / 11 / 2025, page 120 / 176 42 / 77 (((ethyl (methyl)amino)methylene)amino)-2,5-dimethylbenzoate

[0095] A solution of 4-(difluoromethoxy)benzyl 4-(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate (214 mg, 0.548 mmol) was prepared in a mixture of acetone (2.47 mL) and water (0.27 mL) in a 20 mL flask fitted with a magnetic stir bar. Succinic acid (64.7 mg, 0.548 mmol) was added and the resulting clear, colorless solution was stirred at room temperature for 2 hours. The volatiles were removed and the residue was sequentially diluted with the following solvents and then evaporated—diethyl ether (approximately 2 mL), DCM (approximately 2 mL), and hexanes (approximately 2 mL)—to provide a semi-solid foam material. The solid was isolated by suction filtration, washing with hexanes. The titrant compound (70 mg, 0.138 mmol, 25% yield) was isolated as a white foam and as a mixture of isomers: 1H NMR (500 MHz, CD3OD) δ 7.98 - 7.87 (m, 1H), 7.80 (s, 1H), 7.55 - 7.48 (m, 2H), 7.22 - 7.14 (m, 2H), 6.94 (s, 1H) 1.31 (td, J = 7.2, 3.8 Hz, 3H),without COO(H);19F NMR (471 MHz, CD3OD) δ -83.34. Example 12: Crystallization of 4-(difluoromethoxy)benzyl 4-((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate (Formula I) as Form A - evaporative crystallization from ethyl acetate

[0096] 1 g of 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate Petition 870250102165, dated 07 / 11 / 2025, pp. 121 / 176 43 / 77 (Formula I) as a colorless oil was dissolved in ethyl acetate. The solution was concentrated under vacuum with stirring at 35 °C for 5 hours. The oil crystallized into a whitish solid upon cooling to room temperature. A sample was analyzed by powder X-ray diffraction (PXRD) according to Method 1 and received the designation Form A. Example 13: Crystallization of 4(dffluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB) as Form 1 - evaporative crystallization from isopropyl alcohol

[0097] A saturated solution of 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB) was prepared in isopropyl alcohol. The solution was evaporated to dryness at 50 °C without stirring before being placed under vacuum at 50 °C to provide a crystalline solid. A sample was analyzed by powder X-ray diffraction (PXRD) according to Method 2 and given the designation Form 1. Example 14: Alternative crystallization of 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB) as Form 1 - slow evaporative crystallization from acetone or combinations of dichloromethane, ethyl acetate and / or heptane

[0098] 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB, 15 mg) was dissolved in acetone or a combination of dichloromethane, ethyl acetate, and / or heptane in a vial. A needle was inserted through the septum of the cap to allow slow evaporation at temperature. Petition 870250102165, dated 07 / 11 / 2025, pp. 122 / 176 44 / 77 environment to provide crystalline solids. Samples were analyzed by powder X-ray diffraction (PXRD) according to Method 1 and received the designation Form 1. Example 15: Alternative crystallization of 4-(difluoromethoxy)benzyl 4(( ^etzcLl (methyl) amino)methylene) amino)-2,5-dimethylbenzoate hydrochloride (Formula IB) as Form 1 - solvent / antisolvent crystallization of ethanol / methyl tert-butyl ether, acetonitrile / isopropyl acetate, chloroform / heptane or chloroform / methyl isobutyl ketone

[0099] 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB, 25 mg) was completely dissolved in solvent (ethanol, acetonitrile, or chloroform) in a flask. An antisolvent (methyl tert-butyl ether, isopropyl acetate, heptane, or methyl isobutyl ketone) was added dropwise until it reached 4 times the initial volume of the solvent. Samples were shaken at room temperature overnight. If no precipitation occurred, the solutions were placed in a freezer at -20 °C. After precipitation, the samples were filtered to provide crystalline solids. Samples were analyzed by powder X-ray diffraction (PXRD) according to Method 2 and received the designation Form 1. Example 16: Alternative crystallization of 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB) as Form 1 - rapid cooling crystallization from toluene / acetonitrile

[0100] 4-(Difluoromethoxy)benzyl hydrochloride 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate Petition 870250102165, dated 07 / 11 / 2025, pp. 123 / 176 45 / 77 (Formula IB, 25 mg) was dissolved in toluene-acetonitrile (70:30) at 50 °C and the solution was quickly added to an ice bath without stirring. Stirring was initiated after 10 minutes. After precipitation, the sample was filtered to provide a crystalline solid. One sample was analyzed by powder X-ray diffraction (PXRD) according to Method 2 and received the designation Form 1. Example 17: Alternative crystallization of 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB) as Form 1 - crystallization by slow cooling from methyl isobutyl ketone / acetone, ethanol / heptane, toluene / acetonitrile, ethyl acetate / heptane or ethyl acetate / chloroform

[0101] 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB, 25 mg) was added to 2 mL vials. Solvent mixtures (methyl isobutyl ketone / acetone, ethanol / heptane, toluene / acetonitrile, ethyl acetate / heptane, or ethyl acetate / chloroform) were gradually added at 50 °C until complete dissolution. The solutions were slowly cooled to room temperature over approximately 12 hours. If solids did not precipitate after reaching room temperature, the solutions were further cooled to 0 °C or to -20 °C by placing the flask(s) in the freezer overnight. After precipitation, the samples were filtered to yield crystalline solids. Samples were analyzed by powder X-ray diffraction (PXRD) according to Methods 1 and 2 and designated Form 1. Example 18: Alternative crystallization of hydrochloride of Petition 870250102165, dated 07 / 11 / 2025, pp. 124 / 176 46 / 77 4-(difluoromethoxy)benzyl 4-(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate (Formula IB) as Form 1 - crystallization by stagnant cooling of methyl ethyl ketone or mixtures of dichloromethane and heptane

[0102] 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB, 25 mg) was dissolved in methyl ethyl ketone or a mixture of dichloromethane and heptane at 50 °C. The solutions were stored in the freezer. After precipitation, the samples were filtered to provide crystalline solids. Samples were analyzed by powder X-ray diffraction (PXRD) according to Method 2 and received the designation Form 1. Example 19: Crystallization of 4-(difluoromethoxy)benzyl 4-(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB) as Form 2 - evaporative crystallizations of 2-methyl tetrahydrofuran or methyl isobutyl ketone

[0103] A saturated solution of 4(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB) in 2-methyl tetrahydrofuran and an unsaturated solution of Formula IB in methyl isobutyl ketone were prepared. The solutions were evaporated to dryness at 50 °C without stirring before being placed under vacuum at 50 °C to give crystalline solids. Samples were analyzed by powder X-ray diffraction (PXRD) according to Methods 1 and 2 and were designated Form 2. Example 20: Alternative crystallization of 4-(difluoromethoxy)benzyl hydrochloride 4 Petition 870250102165, dated 07 / 11 / 2025, page 125 / 176 47 / 77 (( ^etz:LJ. (methyl) amino)methylene) amino) -2,5-dimethylbenzoate (Formula IB) as Form 2 - solvent / antisolvent crystallization from isopropyl alcohol / methyl tert-butyl ether

[0104] 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB, 25 mg) was completely dissolved in isopropyl alcohol in a flask. An antisolvent (methyl tert-butyl ether) was added dropwise until it reached 4 times the initial volume of the solvent. The sample was stirred at room temperature overnight. If no precipitation occurred, the solution was placed in a freezer at -20 °C. After precipitation, the sample was filtered to provide a crystalline solid. One sample was analyzed by powder X-ray diffraction (PXRD) according to Method 2 and received the designation Form 2. Example 21: Alternative crystallization of 4-(difluoromethoxy)benzyl 4-(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB) as Form 2 - crystallization by slow cooling from methyl isobutyl ketone or heptane / isopropyl alcohol

[0105] 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB, 25 mg) was added to flasks. Methyl isobutyl ketone or a mixture of heptane and isopropyl alcohol was added gradually at 50 °C until the material was completely dissolved. The solutions were cooled slowly to room temperature over approximately 12 hours. If no solids precipitated after reaching room temperature, the solutions were Petition 870250102165, dated 07 / 11 / 2025, pages 126 / 176 48 / 77 were further cooled to 0 °C or to -20 °C by placing them in the freezer overnight. After precipitation, the samples were filtered to provide crystalline solids. Samples were analyzed by powder X-ray diffraction (PXRD) according to Method 2 and received the designation Form 2. Example 22: Crystallization of 4-(difluoromethoxy)benzyl 4-(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB) as Form 3 - evaporative crystallization of methyl isobutyl ketone

[0106] A saturated solution of 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB) in methyl isobutyl ketone was prepared. The solution was evaporated to dryness at 50 °C without stirring before being placed under vacuum at 50 °C to provide a crystalline solid. A sample was analyzed by powder X-ray diffraction (PXRD) according to Method 2 and received the designation Form 3. Example 23: Alternative crystallization of 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB) as Form 3 - rapid cooling crystallization of methyl isobutyl ketone / acetone

[0107] 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB, 25 mg) was dissolved in methyl isobutyl ketone / acetone (70:30) at 50 °C and the solution was rapidly added to an ice bath without stirring. Stirring was initiated after 10 minutes. After precipitation, the sample was Petition 870250102165, dated 07 / 11 / 2025, pp. 127 / 176 49 / 77 filtered to provide a crystalline solid. A sample was analyzed by powder X-ray diffraction (PXRD) according to Method 2 and received the designation Form 3. Example 24: Alternative crystallization of 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB) as Form 3 - slow cooling crystallization from ethyl acetate or tetrahydrofuran / methyl tert-butyl ether

[0108] 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB, 25 mg) was added to flasks. Ethyl acetate or a mixture of tetrahydrofuran and methyl tert-butyl ether was added incrementally at 50 °C until the material was completely dissolved. The solutions were cooled slowly to room temperature over approximately 12 hours. If solids did not precipitate after reaching room temperature, the solutions were further cooled to 0 °C or to -20 °C by placing them in the freezer overnight. After precipitation, the samples were filtered to provide crystalline solids. Samples were analyzed by powder X-ray diffraction (PXRD) according to Methods 1 and 2 and assigned Form 3 designation. Method 1: Powder X-ray Diffraction (PXRD) of Formula I Polymorph Crystalline Form A and Formula IB Forms 1-3

[0109] Samples were analyzed using a Bruker D2 Phaser using Cu Ka radiation (30 kilovolts (kV), 10 milliamperes (mA)) and a θ-θ goniometer. The incident beam passed through a 0.2 millimeter (mm) divergence slit. Petition 870250102165, dated 07 / 11 / 2025, pp. 128 / 176 50 / 77 A 1 mm air scattering screen was placed above the sample and the beam limiter was removed. The diffracted beam passed through a 3 mm air scattering slit, 2.5° Soller slits, and a 0.5 Kβ filter, followed by a Lynxeye SSD160 detector with a 1.5° position-sensitive detector aperture (PSD). Samples were measured under ambient conditions as flat plate specimens using as-received powder. Samples were prepared on a polished, zero-bottom silicon wafer (510) by gently pressing them onto the flat surface or packed into a cut cavity. The sample was rotated in its own plane at 15 rpm. Data were collected from 3 to 40° 2Θ with a step size of 0.03° 2Θ and a collection time of 0.5 seconds. Method 2: Alternative Powder X-ray Diffraction (PXRD) of Polymorph Crystalline Forms 1-3 of Formula IB

[0110] The samples were analyzed using a Bruker D8 Advance X-ray diffraction system equipped with a LYNXEYE detector configured for Bragg-Brentano reflection geometry. The parameters for the PXRD methods used are listed in Table F. Table E: Parameters used in the PXRD 2 method Parameter Regular Scan High Resolution Scan X-ray wavelength Cu Kα1, 1.540598 Cu Kα1, 1.540598 X-ray tube configuration 40 kV, 40 mA 40 kV, 40 mA Slit condition 0.6 mm div. + 2.5° soller 0.6 mm div. + 2.5° soller Scan mode Step Step Petition 870250102165, dated 07 / 11 / 2025, pp. 129 / 176 51 / 77 Parameter Regular Scan High Resolution Scan Range (°2θ) 4-30 4-40 Step Size (°2θ) 0.03 0.02 Dwell Time (s / step) 0.23 0.9 Rotation Yes (0.5 Hz) Yes (0.5 Hz) Table F: Structures of tested compounds Compound Structure Formula I ch3 ch3 F^ / ^^ nn ch.„ F θ.......W ° ch3 Formula IB Hydrochloride Salt of Formula I ch3 ch3 R^ zL^N^N^CH3F / ....... / F ° CH3 Comparator: Example 27 of WO document 2020 / 237131 A1 ch3 ch3 F\^°\ / \ F'.....O.....w ° ch3 Petition 870250102165, dated 07 / 11 / 2025, p. 130 / 176 52 / 77 Compound Structure Comparator: Example 494 of WO document 2020 / 237131 A1 ch3 ch3 NN CH 1 0 . HClF FO CH3 Phosphate Salt of Formula I ch3 ch3 ch3 FyO^^ F H3PO4 O ch3 Fumarate Salt of Formula I ch3 ch3 ch3 F^^O. o ch3OH O Oxalate Salt of Formula I ch3 ch3 ch3 F^ / O. π 1 0H O OH 4- hydroxybenzoate salt of Formula I CH3 CH3 F\zO\ / í\ F.....°......w -uy 0 CH3 Y 0 Succinate salt of Formula I CH3 CH3 F^ / O. / ^ Y,N^N^0 OH0 O CH3F ............ 0....... Petition 870250102165, dated 07 / 11 / 2025, pp. 131 / 176 53 / 77 Details and examples of general biological experiments. Example A: Evaluation of Fungicidal Activity in Belt Sprinkler Applications: Wheat Leaf Septoria (Zymoseptoria tritici; code EPPO SEPTTR):

[0111] The technical grade material of each compound tested was formulated as a 10% emulsifiable concentrate (EC) with one part active ingredient to nine parts of a mixture of water-miscible and water-immiscible solvents and nonionic surfactants, each of which was then mixed with water (H2O) containing 0.1% Break Thru S233 and 0.3% Plurafac LF1300. Details of the EC formulation are provided in Table 1. The fungicide solutions were applied to wheat seedlings using an automatic track sprinkler at a volume of 200 liters per hectare (L / ha) at a pressure of 220 kilopascals (kPa) (2.25 kilograms-force per square centimeter (32 pounds per square inch (psi))). All sprayed plants were allowed to air-dry before further handling. Table 1. Details of the formulations used in this study. Component Function Percentage (%) Technical Material of the Active Ingredient 10% Agnique CSO-25 Emulsifier 10% Atlas G-5002L Emulsifier 5% TamiSolve NxG Solvent 35% N,N-dimethyl decanamide Solvent 40%

[0112] The wheat plants (Yuma variety) were Petition 870250102165, dated 07 / 11 / 2025, pp. 132 / 176 54 / 77 plants were propagated in soilless substrate, with each pot containing 7 to 10 plants, and used for testing when the first leaf was fully emerged. Test plants were inoculated with a spore suspension of Zymoseptoria tritici 3 days before fungicide treatment (3 curative days; 3DC) or 1 day after fungicide treatment (1 protective day; 1DP). After inoculation, the plants were kept at 100% relative humidity for three days to allow the spores to germinate and infect the leaf. The plants were then transferred to a greenhouse for the disease to develop. When disease symptoms were fully expressed on the first leaves of untreated plants, infection levels were visually assessed on a scale of 0 to 100 percent disease severity. Percentage of disease control was calculated using the ratio of disease severity on treated plants to untreated plants.The data are shown in Figure 1.

[0113] Figure 1 shows the percentage of disease control 3 days before fungicide treatment (3 days curative; 3DC) or 1 day after fungicide treatment (1 day protective; 1DP) against test concentrations of Formula I (—♦—) , Example 25 (--»-), Example 27 (-*), Example 494 ( —) and Formula IB (--) . Example B: Evaluation of Fungicidal Activity in Field Trials with Microplots: Wheat Leaf Septoria (Zymoseptoria tritici; code EPPO SEPTTR)

[0114] The technical grade material of each compound tested was formulated as a 10% emulsifiable concentrate (EC) with one part active ingredient to nine parts of a mixture of water-miscible and immiscible solvents. Petition 870250102165, dated 07 / 11 / 2025, pp. 133 / 176 55 / 77 in water and nonionic surfactants, each of which was then mixed with water (H2O) containing 0.1% Break Thru S233 and 0.3% Plurafac LF1300. Details of the EC formulation are provided in Table 1. The fungicide solutions were applied to 1-meter by 2-meter plots of wheat plants using a backpack sprayer and a flat fan nozzle at a volume of 200 L / ha at a pressure of 220 kPa.

[0115] Wheat plants (varieties “Lancer”, “Barrel”, and “Tobak”) were established in 1-meter by 2-meter microplots, and materials were applied at a curative application time between growth stages 39 and 55 or at a protective application time between growth stages 37 and 39, depending on the geographic region. Four replicates were used in a randomized block design. Disease severity on a scale of 0 to 100 percent was visually assessed at various time points over an interval of approximately 7 to 14 days to generate the percent disease control based on the area under the disease progress curve. Tests were conducted in up to three geographic locations. Data are shown in Figure 2.

[0116] Figure 2 shows the percentage of disease control in relation to the test concentrations of

[0117] Formula I (—♦—) and Example 25 (--»-) in a cross-test analysis of replicated field trials. Example C: Evaluation of Fungicidal Activity in Field Trials with Microplots: Barley Net Blot (Pyrenophora teres; code EPPO PYRNTE)

[0118] The technical grade material of each compound tested was formulated as an emulsifiable concentrate (EC) Petition 870250102165, dated 07 / 11 / 2025, pp. 134 / 176 56 / 77 of 10% with one part active ingredient to nine parts of a mixture of water-miscible and water-immiscible solvents and nonionic surfactants, each of which was then mixed with water (H2O) containing 0.1% Break Thru S233 and 0.3% Plurafac LF1300. Details of the EC formulation are provided in Table 1. The fungicide solutions were applied to 1-meter by 2-meter plots of barley plants using a backpack sprayer and a flat fan nozzle at a volume of 200 L / ha at a pressure of 240-250 kPa.

[0119] Barley plants (varieties “Snakebite”, “Planet”, and “LG Caspari”) were established in 1-meter by 2-meter microplots, and protective materials were applied at a time between growth stages 45 and 49, depending on the geographic region. Four replicates were used in a randomized block design. Disease severity on a scale of 0 to 100 percent was visually assessed at various time points over approximately 7-day intervals to generate percent disease control based on the area under the disease progress curve. Tests were conducted in up to three geographic locations. Data are shown in Figure 3.

[0120] Figure 3 shows the percentage of disease control in relation to the test concentrations of

[0121] Formula I (—) and Example 25 (--»-) in a cross-test analysis of replicated field trials. Example D: Evaluation of Fungicidal Activity in Field Trials with Microplots: Ramularia leaf spot in barley (Ramularia collo-cygni; EPPO code RAMUCC)

[0122] The technical grade material of each compound Petition 870250102165, dated 07 / 11 / 2025, pages 135 / 176 The 57 / 77 tested was formulated as a 10% emulsifiable concentrate (EC) with one part active ingredient to nine parts of a mixture of water-miscible and water-immiscible solvents and nonionic surfactants, each of which was then mixed with water (H2O) containing 0.1% Break Thru S233 and 0.3% Plurafac LF1300. Details of the EC formulation are provided in Table 1. The fungicide solutions were applied to 1-meter by 2-meter plots of barley plants using a backpack sprayer and a flat fan nozzle at a volume of 200 L / ha at a pressure of 250-300 kPa.

[0123] Barley plants (Taverna, Lomerit, and LG Caspari varieties) were established in 1-meter by 2-meter microplots, and protective materials were applied at a time between growth stages 33 and 41, depending on the geographic region. Four replicates were used in a randomized block design. Disease severity on a scale of 0 to 100 percent was visually assessed at various time points over an interval of approximately 7 to 14 days to generate percent disease control based on the area under the disease progress curve. Tests were conducted in up to three geographic locations. Data are shown in Figure 4.

[0124] Figure 4 shows the percentage of disease control in relation to the test concentrations of

[0125] Formula I (—♦—) and Example 25 (--»-) in a cross-test analysis of replicated field trials. Example E: Evaluation of Fungicidal Activity in Field Trials with Microplots: Barley Scald (Rhynchosporium secaii; code EPPO RHYNSE) Petition 870250102165, dated 07 / 11 / 2025, pages 136 / 176 58 / 77

[0126] The technical grade material of each compound tested was formulated as a 10% emulsifiable concentrate (EC) with one part active ingredient to nine parts of a mixture of water-miscible and water-immiscible solvents and nonionic surfactants, each of which was then mixed with water (H2O) containing 0.1% Break Thru S233 and 0.3% Plurafac LF1300. Details of the EC formulation are provided in Table 1. The fungicide solutions were applied to 1 by 2 meter plots of barley plants using a backpack sprayer and a flat fan nozzle at a volume of 200 L / ha at a pressure of 250-300 kPa.

[0127] Barley plants (Snakebite and Pixel varieties) were established in 1-meter by 2-meter microplots, and protective materials were applied at a time between growth stages 33 and 41, depending on the geographic region. Four replicates were used in a randomized block design. Disease severity on a scale of 0 to 100 percent was visually assessed at various time points over an interval of approximately 7 to 14 days to generate percent disease control based on the area under the disease progress curve. Tests were conducted in up to three geographic locations. Data are shown in Figure 5.

[0128] Figure 5 shows the percentage of disease control in relation to the test concentrations of

[0129] Formula I (—) and Example 25 (--»-) in a cross-test analysis of replicated field trials. Example F: Evaluation of Fungicidal Activity in Field Trials with Microplots: Barley Rust (Puccinia hordei; code EPPO PUCCHD)

[0130] The technical grade material of each compound Petition 870250102165, dated 07 / 11 / 2025, pages 137 / 176 The tested 59 / ΊΊ was formulated as a 10% emulsifiable concentrate (EC) with one part active ingredient to nine parts of a mixture of water-miscible and water-immiscible solvents and nonionic surfactants, each of which was then mixed with water (H2O) containing 0.1% Break Thru S233 and 0.3% Plurafac LF1300. Details of the EC formulation are provided in Table 1. The fungicide solutions were applied to 1-meter by 2-meter plots of barley plants using a backpack sprayer and a flat fan nozzle at a volume of 200 L / ha at a pressure of 200-300 kPa.

[0131] Barley plants (Pixel and Faro varieties) were established in 1-meter by 2-meter microplots, and protective materials were applied at a time between growth stages 41 and 65, depending on the geographic region. Four replicates were used in a randomized block design. Disease severity on a scale of 0 to 100 percent was visually assessed at various time points over an interval of approximately 7 to 14 days to generate percent disease control based on the area under the disease progress curve. Tests were conducted in up to three geographic locations. Data are shown in Figure 6.

[0132] Figure 6 shows the percentage of disease control in relation to the test concentrations of

[0133] Formula I (—) and Example 25 (--»-) in a cross-test analysis of replicated field trials. Example G: Evaluation of Fungicidal Activity: Cercospora Leaf Spot in Beetroot (Cercospora beticola; EPPO code CERCBE)

[0134] The technical grade material of each compound Petition 870250102165, dated 07 / 11 / 2025, pp. 138 / 176 The 60 / 77 tested fungicide was dissolved in acetone, which was then mixed with nine volumes of water (H2O) containing 110 ppm of Triton X100. The fungicide solutions were applied to beet seedlings using an automatic spray booth sprayer for runoff. All sprayed plants were allowed to air dry before further handling.

[0135] Sugar beet plants (variety SV333) were propagated in soilless substrate, with each pot containing 1 plant, and used for testing when the first leaf was fully emerged. Test plants were inoculated with a 1-day Cercospora beticola spore suspension (1-day protectant; 1DP) after fungicide treatment. After inoculation, the plants were kept in a dark dew room with 100% relative humidity for two days to allow the spores to germinate and infect the leaf. The plants were then transferred to a greenhouse for the disease to develop. Disease assessment was conducted as described in Example A. The data are shown in Table 2. Example H: Evaluation of Fungicidal Activity: Anthracnose of Cucurbits (Colletotrichum orbiculare; code EPPO COLLLA)

[0136] Cucumber seedlings (Bush Pickle variety) were propagated in soilless substrate, with each pot containing 1 plant, and used for testing when the first leaf was fully emerged. Test plants were inoculated with a spore suspension of Colletotrichum orbiculare one day after fungicide treatments (1-day protectant; 1DP). After inoculation, the plants were kept at 100% relative humidity for two days to allow the spores to germinate and infect the leaf. The plants were then Petition 870250102165, dated 07 / 11 / 2025, pp. 139 / 176 61 / 77 transferred to a greenhouse to allow the disease to develop. Fungicide formulation and application were performed as described in Example G. Disease assessment was conducted as described in Example A. The data are shown in Table 2. Example I: Evaluation of Fungicidal Activity: Rice Blast (Magnaporthe oryzae; code EPPO PYRIOR)

[0137] Rice seedlings (M202 variety) were propagated in soilless potting mix, with each pot containing 8 to 10 plants, and used for testing when the first leaf was fully submerged. Test plants were inoculated with a spore suspension of Magnaporthe oryzae one day after fungicide treatments (1-day protectant; 1DP). After inoculation, the plants were kept at 100% relative humidity for two days to allow the spores to germinate and infect the leaf. The plants were then transferred to a greenhouse for disease development. Fungicide formulation and application were as described in Example G. Disease assessment was conducted as described in Example A. Data are shown in Table 2. Table 2. Fungicidal activity as a percentage of disease control in a 1-day protective application at 200 and 50 ppm. Percentage (%) of Disease Control | 1-Day Compound Protector No. CERCBE COLLLA PYRIOR 200 ppm 50 ppm 200 ppm 50 ppm 200 ppm 50 ppm Example 25 53 0 80 2 37 5 Example 494 88 28 74 56 70 52 Example 27 85 68 91 11 74 0 Formula I 88 91 98 92 85 44 Petition 870250102165, dated 07 / 11 / 2025, pp. 140 / 176 62 / 77 Percentage (%) of Disease Control | 1-Day Compound Protector No. CERCBE COLLLA PYRIOR 200 ppm 50 ppm 200 ppm 50 ppm 200 ppm 50 ppm Formula IB 72 63 95 55 94 29 Example J: Evaluation of Fungicidal Activity: Rust Asian Soybean (Phakopsora pachyrhizi; EPPO code PHAKPA)

[0138] The technical grade material of each compound tested was dissolved in acetone, each of which was then mixed with nine volumes of water (H2O) containing 0.011% Tween 20. The fungicide solutions were applied to soybean seedlings using an automatic spray booth sprayer for runoff. All sprayed plants were allowed to air dry before further handling.

[0139] Soybean plants (variety “Williams 82”) were propagated in soilless substrate, with each pot containing 1 plant, and used for testing when the first leaf was fully emerged. The test plants were inoculated as described in Example A. After inoculation, the plants were kept at 100% relative humidity for 24 hours to allow spores to germinate and infect the leaf. The plants were transferred to a growth chamber for the disease to develop. Fungicide application and disease assessment were performed as described in Example A. The data are shown in Table 3. Table 3. Fungicidal activity as a percentage of disease control in 1-day protective (1DP) and 3-day curative (3DC) applications at 200, 50, 12.5 and 3,125 ppm. Petition 870250102165, dated 07 / 11 / 2025, pp. 141 / 176 63 / 77 Percentage (%) of Disease Control | PHAKPA Compound No. 1DP 3DC 200 ppm 50 ppm 12.5 ppm 3.125 ppm 200 ppm 50 ppm 12.5 ppm 3.125 ppm Example 25 100 100 100 76 99 98 96 71 Example 27 100 100 97 55 100 99 95 77 Example 494 100 100 100 98 100 99 99 88 Formula I 100 100 100 86 98 100 100 86 Formula I-B 100 100 99 81 100 100 96 63 Example K: Fungicidal Activity Assessment: Tomato Black Spot (Alternaria solani; code EPPO ALTESO)

[0140] Tomato seedlings (variety “Brandywine”) were propagated in soilless potting mix, where each pot had 1 plant and was used for testing when the first leaf was fully submerged. Test plants were inoculated with a spore suspension of Alternaria solani one day after fungicide treatments (1-day protectant; 1DP). After inoculation, the plants were kept in a dark dew room with 100% relative humidity for 2 days to allow the spores to germinate and infect the leaf. The plants were then transferred to a greenhouse for disease development. Fungicide formulation and application were as described in Example G. Disease assessment was conducted as described in Example A. The data are shown in Table 4. Table 4. Fungicidal activity as a percentage of disease control in a 1-day protective application (1DP) at 200 and 50 ppm. Petition 870250102165, dated 07 / 11 / 2025, pp. 142 / 176 64 / 77 Percentage (%) of Disease Control | ALTESO Compound No. 1DP 200 ppm 50 ppm Example 25 98 79 Example 27 99 97 Example 494 97 78 Formula I 100 100 Formula IB 100 99 Example L: Fungicidal Activity Assessment: Gray Mold (Botrytis cinerea; EPPO code BOTRCI)

[0141] Grape plants (variety “Pinot noir”) were propagated in soilless substrate, with each pot containing 1 plant and trimmed to the first fully emerged leaf. Test plants were inoculated with a Botrytis cinerea spore suspension one day after fungicide treatments (1-day protectant; 1DP). After inoculation, the plants were kept in a dark dew room with 100% relative humidity for 4 days to allow the spores to germinate and infect the leaf. The plants were then transferred to a greenhouse for the disease to develop. The fungicide formulation and application were as described in Example G. Disease assessment was conducted as described in Example A. The data are shown in Table 5. Table 5. Fungicidal activity as a percentage of disease control in a 1-day protective application (1DP) at 200 and 50 ppm. Petition 870250102165, dated 07 / 11 / 2025, pp. 143 / 176 65 / 77 Percentage (%) of Disease Control | BOTRCI Compound No. 1DP 200 ppm 50 ppm Example 25 100 94 Example 27 99 100 Example 494 99 95 Formula I 100 100 Formula IB 100 100 Example M: ​​Fungicidal Activity Assessment: Cucurbit Powdery Mildew (Podosphaera xanthii; code EPPO PODOXA)

[0142] Cucumber plants (variety “Straight eight”) were propagated in soilless substrate, with each pot containing 1 plant, and used for testing when the first leaf was fully emerged. Test plants were inoculated with a spore suspension of Podosphaera xanthii one day after fungicide treatments (1-day protectant; 1DP). After inoculation, the plants were then transferred to a greenhouse for disease development. Fungicide formulation and application were as described in Example G. Disease assessment was conducted as described in Example A. Data are shown in Table 6. Table 6. Fungicidal activity as a percentage of disease control in a 1-day protective application (1DP) at 200 and 50 ppm. Percentage (%) of Disease Control | PODOXA Compound No. 1DP 200 ppm 50 ppm Example 25 100 98 Petition 870250102165, dated 07 / 11 / 2025, pp. 144 / 176 66 / 77 Percentage (%) of Disease Control | PODOXA Compound No. 1DP 200 ppm 50 ppm Example 27 99 100 Example 494 100 100 Formula I 100 98 Formula IB 100 98 Example N: Evaluation of In vitro Fungicidal Activity: Cercospora kikuchii, code EPPO CERCKI; Corynespora cassiicola, code EPPO CORYCA and Septoria glycines, code EPPO SEPTGL

[0143] The test compounds were serially diluted in dimethyl sulfoxide (DMSO) and 2 microliter (μL) aliquots were added to 96-well flat-bottom microtiter plates (Falcon Products).

[0144] Fungal cultures of Cercospora kikuchii, Corynespora cassiicola and Septoria glycines were cultured for 7 to 14 days on potato dextrose agar (BD DIFCO™ product 213400) or V-8 agar (V8 juice 200.0 ml (mL), calcium carbonate (CaCO3) 3.0 g, sucrose 1 g, agar 15.0 g / L) pH 7.2 ± 0.2 until sporulation. Spore suspensions were prepared in Difco YNB (6.7 g / L, yeast nitrogen base without amino acids; BD Diagnostic Systems) supplemented with 2 g of glucose and 3 g of potassium dihydrogen phosphate and dipotassium hydrogen phosphate per liter (L). The total assay volume was 200 μL per well. Plates were incubated for 3–5 days at 22 °C and growth inhibition was assessed using a NepheloStar nephelometer (BMG LABTECH). The percentage of growth inhibition was calculated with reference to Petition 870250102165, dated 07 / 11 / 2025, pages 145 / 176 67 / 77 control wells containing growth medium and inoculum altered with 1% DMSO. The data are shown in Table 7. Table 7. Percentage (%) of fungal growth inhibition in vitro at 10, 2, 0.4 and 0.08 ppm Percentage (%) of Inhibition | CERCKI | CORYCA | SEPTGL Organism CERCKI CORYCA SEPTGL Test Concentration (ppm) 10 2 0.4 0.08 10 2 0.4 0.08 10 2 0.4 0.08 Example 25 70 6 0 50 20 90 9 0 60 0 90 10 0 70 0 Example 494 10 0 8 0 70 60 10 0 9 0 40 0 ​​10 0 90 80 10 Example 27 70 5 0 50 50 10 0 9 0 80 40 10 0 10 0 10 0 90 Formula I 80 5 0 50 30 10 0 9 0 10 0 30 10 0 10 0 10 0 90 Formula I-B 70 6 0 50 40 90 9 0 10 0 40 10 0 10 0 10 0 100 Example O: Evaluation of Fungicidal Activity: Wheat Leaf Brown Rust (Puccinia triticina; Synonym: Puccinia recondita f. sp. tritici; Bayer code PUCCRT):

[0145] Wheat plants (Yuma variety) were grown from seed in a greenhouse in a soilless potting mix until the first leaf fully emerged, with 7-10 seedlings per pot. These plants were inoculated with an aqueous spore suspension of Puccinia triticina after fungicide treatments. After inoculation, the plants were kept in a dark, dew-free room with Petition 870250102165, dated 07 / 11 / 2025, pages 146 / 176 68 / 77 100% relative humidity overnight to allow spores to germinate and infect the leaf. The plants were then transferred to a greenhouse for the disease to develop. Fungicide formulation and application were as described in Example G. Disease assessment was conducted as described in Example A. The data are shown in Table 8. Table 8. Fungicidal activity as a percentage of disease control in a 1-day protective application (1DP) at 200, 50, 12.5 and 3.125 ppm. Percentage (%) Disease | PUCCRT Control of Compound 1DP 200 ppm 50 ppm 12.5 ppm 3.125 ppm Example 25 100 100 100 100 Example 27 100 100 98 24 Example 494 97 98 93 86 Formula I 100 100 100 53 Formula I-B 100 100 100 53 Example P: Assessment of In vitro Fungicide Activity: Alternaria solani, EPPO code ALTESO; Botrytis cinerea, EPPO code BOTRCI; Colletotrichum orbiculare, EPPO code COLLLA; Corynespora cassiicola, EPPO code CORYCA; Magnaporthe oryzae, EPPO code PYRIOR; Zymoseptoria tritici, EPPO code SEPTTR and Ustilago maydis, EPPO code USTIMA

[0146] The test compounds were diluted in dimethyl sulfoxide (DMSO) and 2 microliter (µL) aliquots were added to flat-bottom microtiter plates. Petition 870250102165, dated 07 / 11 / 2025, pp. 147 / 176 69 / 77 of 96 wells (Falcon Products).

[0147] Spore suspensions were prepared in Difco YNB (6.7 g / L, amino acid-free yeast nitrogen base; BD Diagnostic Systems) supplemented with 2 g of glucose and 3 g of potassium dihydrogen phosphate and dipotassium hydrogen phosphate per liter (L). The total assay volume was 200 pL per well. The initial inoculum density was adjusted to 100,000 spores / mL for BOTRCI, CORYCA, and SEPTTR, 250,000 spores / mL for COLLLA, 40,000 spores / mL for PYRIOR, 50,000 spores / mL for USTIMA, and 10,000–20,000 spores / mL for ALTESO.

[0148] Immediately after the addition of the spore suspensions, initial cell density readings were determined using a NepheloStar nephelometer (BMG LABTECH GmbH, Ortenberg, Germany). After incubation in a New Brunswick Innova 44 incubator (Eppendorf, Inc., Enfield, CT) for 48 hours at 22 °C (ALTESO, BOTRCI, PYRIOR, and USTIMA), 72 hours at 22 °C (SEPTTR), 96 hours at 22 °C (CORYCA), or 96 hours at 28 °C (COLLLA), the plates were read on the NepheloStar a second time to assess growth. The percentage of growth inhibition was calculated with reference to control wells containing growth medium and inoculum altered with 1% DMSO. The data are shown in Table 9. Table 9. Percentage (%) of fungal growth inhibition in vitro at 5 ppm Percentage inhibition of fungal growth in vitro Free base form Salt form ALTESO BOTRCI COLLLA CORYCA PYRIOR SEPTTR USTIMA Formula I None (free base) 6 0 5 0 1 0 1 0 7 0 8 0 9 0 Petition 870250102165, dated 07 / 11 / 2025, pages 148 / 176 70 / 77 Percentage inhibition of fungal growth in vitro Free base form Salt form ALTESO BOTRCI COLLLA CORYCA PYRIOR SEPTTR USTIMIA 0 0 Formula I Hydrochloride (Formula IB) 7 0 1 0 0 1 0 0 1 0 0 8 0 9 0 9 0 Formula I Phosphate N / A 9 0 1 0 0 1 0 0 7 0 8 0 7 0 Formula I Fumarate 4 0 9 0 1 0 0 1 0 0 8 0 8 0 7 0 Formula I Oxalate 6 0 9 0 1 0 0 1 0 0 7 0 7 0 6 0 Formula I Tartrate 6 0 9 0 1 0 0 1 0 0 5 0 8 0 5 0 Formula I 4-Hydroxybenzoate 4 0 8 0 1 0 0 1 0 0 4 0 7 0 1 0 Formula I Succinate 5 0 8 0 1 0 0 1 0 0 5 0 8 0 6 0 Example 25 None (free base) 6 0 7 0 7 0 1 0 0 6 0 8 0 9 0 Example 25 Hydrochloride (Example 494 of document no. WO 2020 / 237131 N / N / N / 1 0 7 0 9 0 9 0 Petition 870250102165, dated 07 / 11 / 2025, pp. 149 / 176 71 / 77 Percentage inhibition of fungal growth in vitro Free base form Salt form ALTESO BOTRCI COLLLA CORYCA PYRIOR SEPTTR USTIMA A1) AAA 0

[0149] In light of the foregoing, the compounds of this disclosure may be described as embodiments in any of the following enumerated clauses. It shall be understood that any of the embodiments described herein may be used in connection with any other embodiments described herein, to the extent that the embodiments do not contradict each other. 1. A crystalline form of 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate (Formula I). 2. The crystalline form of embodiment 1, wherein the crystalline form is a polymorphic crystalline form of 4-(difluoromethoxy)benzyl 4-(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate (Formula I). 3. The crystalline form of embodiment 1 or 2, wherein the crystalline form is an anhydrous, solvent-free polyphasic crystalline form. 4. A Form A of crystalline polymorph of 4(difluoromethoxy)benzyl 4-(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate (Formula I) having a powder X-ray diffraction pattern comprising a peak at the diffraction angle (2θ) of 23.3 ± 0.2. 5. The crystalline polymorph form of embodiment 4, wherein the crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of Petition 870250102165, dated 07 / 11 / 2025, pp. 150 / 176 72 / 77 12.4 ± 0.2 and 23.3 ± 0.2. 6. The crystalline polymorph form of embodiment 4 or 5, wherein the crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 12.4 ± 0.2, 23.3 ± 0.2 and 27.1 ± 0.2. 7. The crystalline polymorph form of any of embodiments 4 to 6, wherein the crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 12.4 ± 0.2, 21.6 ± 0.2, 23.3 ± 0.2 and 27.1 ± 0.2. 8. The crystalline polymorph form of any of the embodiments 4 to 7, wherein the crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 5.5 ± 0.2, 12.4 ± 0.2, 21.6 ± 0.2, 23.3 ± 0.2 and 27.1 ± 0.2. 9. The crystalline polymorph form of any of embodiments 4 to 8, wherein the crystalline form has a powder X-ray diffraction pattern comprising one or more peaks essentially identical to those shown in Figure 7. 10. A crystalline form of 4-(difluoromethoxy)benzyl 4-(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB). 11. The crystalline form of embodiment 10, wherein the crystalline form is a polymorphic crystalline form of 4-(difluoromethoxy)benzyl 4-(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB). 12. The crystalline form of embodiment 10 or 11, wherein the crystalline form is a polymorphic crystalline hemihydrate form. Petition 870250102165, dated 07 / 11 / 2025, pp. 151 / 176 73 / 77 13. A Form 1 of crystalline polymorph of 4-(difluoromethoxy)benzyl 4-(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB) with a powder X-ray diffraction pattern comprising a peak at the diffraction angle (2θ) of 23.6 ± 0.2. 14. The crystalline polymorph form of embodiment 13, wherein the crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 12.1 ± 0.2 and 23.6 ± 0.2. 15. The crystalline polymorph form of embodiment 13 or 14, wherein the crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 12.1 ± 0.2, 18.7 ± 0.2 and 23.6 ± 0.2. 16. The crystalline polymorph form of any of the embodiments 13 to 15, wherein the crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 10.5 ± 0.2, 12.1 ± 0.2, 18.7 ± 0.2 and 23.6 ± 0.2. 17. The crystalline polymorph form of any of the embodiments 13 to 16, wherein the crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 10.5 ± 0.2, 12.1 ± 0.2, 18.7 ± 0.2, 23.6 ± 0.2 and 25.9 ± 0.2. 18. The crystalline polymorph form of any of the embodiments 13 to 17, wherein the crystalline form has a powder X-ray diffraction pattern comprising one or more peaks essentially identical to those shown in Figure 8. 19. The crystalline form of embodiment 10 or 11, wherein the crystalline form is an anhydrous, solvent-free polymorphic crystalline form. 20. A Form 2 crystalline polymorph of hydrochloride Petition 870250102165, dated 07 / 11 / 2025, pp. 152 / 176 4 / 77 of 4-(difluoromethoxy)benzyl 4(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate (Formula IB) having a powder X-ray diffraction pattern comprising a peak at the diffraction angle (2θ) of 9.6 ± 0.2. 21. The crystalline polymorph form of embodiment 20, wherein the crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 9.6 ± 0.2 and 21.6 ± 0.2. 22. The polymorphic crystalline form of embodiment 20 or 21, wherein the crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 4.9 ± 0.2, 9.6 ± 0.2 and 21.6 ± 0.2. 23. The polymorphic crystalline form of any of the embodiments 20 to 22, wherein the crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 4.9 ± 0.2, 9.6 ± 0.2, 21.6 ± 0.2 and 24.5 ± 0.2. 24. The crystalline polymorph form of any of the embodiments 20 to 23, wherein the crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 4.9 ± 0.2, 9.6 ± 0.2, 16.1 ± 0.2, 21.6 ± 0.2 and 24.5 ± 0.2. 25. The crystalline polymorph form of any of the embodiments 20 to 24, wherein the crystalline form has a powder X-ray diffraction pattern comprising one or more peaks essentially identical to those shown in Figure 9. 26. A Form 3 crystalline polymorph of 4-(difluoromethoxy)benzyl 4-(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB) having a powder X-ray diffraction pattern Petition 870250102165, dated 07 / 11 / 2025, pp. 153 / 176 75 / 77 which comprises a peak at the diffraction angle (2θ) of 9.4 ± 0.2. 27. The crystalline polymorph form of embodiment 26, wherein the crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 4.7 ± 0.2 and 9.4 ± 0.2. 28. The crystalline polymorph form of embodiment 26 or 27, wherein the crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 4.7 ± 0.2, 9.4 ± 0.2 and 19.0 ± 0.2. 29. The crystalline polymorph form of any of the embodiments 26 to 28, wherein the crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 4.7 ± 0.2, 9.4 ± 0.2, 19.0 ± 0.2 and 24.7 ± 0.2. 30. The crystalline polymorph form of any of the embodiments 26 to 29, wherein the crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 4.7 ± 0.2, 9.4 ± 0.2, 19.0 ± 0.2, 21.1 ± 0.2 and 24.7 ± 0.2. 31. The crystalline polymorph form of any of the embodiments 26 to 30, wherein the crystalline form has a powder X-ray diffraction pattern comprising one or more peaks essentially equal to those shown in Figure 10.

[0150] All references, including publications, patent applications and patents, cited in this document are incorporated herein by reference as if each reference were individually and specifically indicated as incorporated by reference and presented in its entirety in this document. Petition 870250102165, dated 07 / 11 / 2025, pp. 154 / 176 6 / 77

[0151] The use of the terms “a” and “an” and “the” and “at least one” and similar referents in the context of this disclosure (especially in the context of the claims) should be interpreted to cover both the singular and plural, unless otherwise indicated herein or clearly contradicted by the context. The use of the term “at least one” followed by a list of one or more items (e.g., “at least one of A and B”) should be interpreted as meaning an item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by the context. The terms “comprise,” “have,” “include,” and “contain” should be interpreted as open-ended terms (i.e., meaning including, but not limited to), unless otherwise specified.The mention of value ranges in this document is intended only as a summary method for individually referring to each separate value within the range, unless otherwise indicated in this document, and each separate value is incorporated into the descriptive report as if it had been individually mentioned in this document. All methods described in this document may be performed in any suitable order unless otherwise indicated or clearly contradicted by the context. The use of any and all examples or exemplary language (e.g., “as”) provided in this document is intended only to better clarify this disclosure and does not represent a limitation on the scope of the disclosure, unless otherwise stated. No language in the descriptive report should be construed as indicating any... Petition 870250102165, dated 07 / 11 / 2025, pages 155 / 176 77 / 77 element not claimed as essential to the practice of any implementation in this document. Petition 870250102165, dated 07 / 11 / 2025, pp. 156 / 176

Claims

1 / 7 CLAIMS 1. Compound, characterized in that it is of Formula I: Formula I or an acceptable salt, solvate or hydrate thereof.

2. Compound according to claim 1, characterized in that the acceptable salt is selected from the group consisting of hydrochloride, phosphate, oxalate, tartrate, fumarate, succinate and 4-hydroxybenzoate.

3. Compound according to claim 1 or 2, characterized in that the acceptable salt is hydrochloride.

4. Compound according to claim 3, characterized in that it is 4-(difluoromethoxy)benzyl 4-(((ethyl(methyl)amino)methylene)amino)-2,5-dimethylbenzoate hydrochloride (Formula IB).

5. Compound, according to any one of claims 1 to 4, characterized in that it is for use in controlling a fungal pathogen.

6. Compound, according to claim 5, characterized in that the fungal pathogen is one of Zymoseptoria tritici, Cochliobolus sativus, Puccinia triticina, Puccinia striiformis, Ustilago maydis, Uncinula necator, Rhynchosporium secalis, Magnaporthe oryzae, Phakopsora pachyrhizi, Parastagonospora nodorum, Colletotrichum orbiculare, Puccinia hordei, Cercospora beticola, Alternaria solani, Pyrenophora teres, Blumeria Petition 870250102165, of 07 / 11 / 2025, pág. 157 / 176 2 / 7 graminis f. sp. tritici, Blumeria graminis f. sp. hordei, Erysiphe cichoracearum, Podosphaera xanthii, Rhizoctonia solani, Botrytis cinerea, Ramularia collo-cygni, Pyrenophora tritici-repentis, Exserohilum turcicum, Puccinia polysora, Sclerotinia sclerotiorum, Erysiphe diffusa, Podosphaera leucotricha, Colletotrichum truncatum, Cercospora kikuchii, Cercospora sojina, Corynespora cassiicola, and Septoria glycines.

7. A compound according to claim 6, characterized in that the fungal pathogen is one of Zymoseptoria tritici, Pyrenophora teres, Ramularia collocygni, Rhynchosporium secalis, Puccinia hordei, Cercospora beticola, Colletotrichum orbiculare, Magnaporthe oryzae, Phakopsora pachyrhizi, Alternaria solani, Botrytis cinerea, Podosphaera xanthii, Cercospora kikuchii, Corynespora cassiicola, Septoria glycines, Ustilago maydis, and Puccinia triticina.

8. Compound, according to claim 5, characterized in that it treats one of the following diseases caused by the fungal pathogen: Wheat leaf septoria (Zymoseptoria tritici), barley brown spot (Cochliobolus sativus), wheat leaf brown rust (Puccinia triticina), wheat yellow rust (Puccinia striiformis), corn smut (Ustilago maydis), vine powdery mildew (Uncinula necator), barley scald (Rhynchosporium secalis), rice blast (Magnaporthe oryzae), Asian soybean rust (Phakopsora pachyrhizi), wheat glume blotch (Parastagonospora nodorum), cucurbit anthracnose (Colletotrichum orbiculare), barley rust (Puccinia hordei), beet cercospora leaf spot (Cercospora beticola), black spot Petition 870250102165, dated 07 / 11 / 2025, p. 158 / 176 3 / 7 of tomato (Alternaria solani), nettle spot of barley (Pyrenophora teres), powdery mildew of wheat (Blumeria graminis f. sp.Powdery mildew of barley (Blumeria graminis f. sp. hordei), powdery mildew of cucurbits (Erysiphe cichoracearum), powdery mildew of cucumber (Podosphaera xanthii), root rot (Rhizoctonia solani), gray mold (Botrytis cinerea), ramularia leaf spot in barley (Ramularia collocygni), yellow spot of wheat (Pyrenophora triticirepentis), corn leaf blight (Exserohilum turcicum), corn polysora rust (Puccinia polysora), white mold (Sclerotinia sclerotiorum), powdery mildew of soybeans (Erysiphe diffusa), powdery mildew of apple (Podosphaera leucotricha), anthracnose of soybeans (Colletotrichum truncatum), soybean leaf blight (Cercospora kikuchii), frog-eye leaf spot of soybeans (Cercospora sojina), soybean target spot (Corynespora cassiicola) and soybean brown spot (Septoria glycines).

9. Compound according to claim 8, characterized in that it treats one of the following diseases caused by the fungal pathogen: Wheat leaf blight (Zymoseptoria tritici), nettle blotch of barley (Pyrenophora teres), ramularia leaf spot in barley (Ramularia collo-cygni), barley scald (Rhynchosporium secalis), barley rust (Puccinia hordei), cercospora leaf spot in beet (Cercospora beticola), anthracnose of cucurbits (Colletotrichum orbiculare), rice blast (Magnaporthe oryzae), Asian soybean rust (Phakopsora pachyrhizi), tomato black spot (Alternaria solani), gray mold (Botrytis cinerea), powdery mildew of cucurbits (Podosphaera xanthii), soybean leaf blight (Cercospora). kikuchii), target spot of soybean (Corynespora cassiicola), brown spot of soybean Petition 870250102165, dated 07 / 11 / 2025, page.159 / 176 4 / 7 (Septoria glycines), corn smut (Ustilago maydis) and brown rust of wheat leaf (Puccinia triticina).

10. Composition for use in controlling a fungal pathogen, characterized in that it comprises a phytologically acceptable amount of the compound defined in any one of claims 1 to 4, and a carrier.

11. Composition, according to claim 10, characterized by the fact that the fungal pathogen is one of Zymoseptoria tritici, Cochliobolus sativus, Puccinia triticina, Puccinia striiformis, Ustilago maydis, Uncinula necator, Rhynchosporium secalis, Magnaporthe oryzae, Phakopsora pachyrhizi, Parastagonospora nodorum, Colletotrichum orbiculare, Puccinia hordei, Cercospora beticola, Alternaria solani, Pyrenophora teres, Blumeria graminis f. sp. tritici, Blumeria graminis f. sp. hordei, Erysiphe cichoracearum, Podosphaera xanthii, Rhizoctonia solani, Botrytis cinerea, Ramularia collo-cygni, Pyrenophora tritici-repentis, Exserohilum turcicum, Puccinia polysora, Sclerotinia sclerotiorum, Erysiphe diffusa, Podosphaera leucotricha, Colletotrichum truncatum, Cercospora kikuchii, Cercospora sojina, Corynespora cassiicola, and Septoria glycines.

12. Composition, according to claim 11, characterized in that the fungal pathogen is one of Zymoseptoria tritici, Pyrenophora teres, Ramularia collocygni, Rhynchosporium secalis, Puccinia hordei, Cercospora beticola, Colletotrichum orbiculare, Magnaporthe oryzae, Phakopsora pachyrhizi, Alternaria solani, Botrytis cinerea, Podosphaera xanthii, Cercospora kikuchii, Corynespora cassiicola, Septoria glycines, Ustilago maydis, and Puccinia triticina. Petition 870250102165, dated 07 / 11 / 2025, pp. 160 / 176 5 / 7 13. Composition, according to claim 10, characterized in that it treats one of the following diseases caused by the fungal pathogen: Wheat leaf septoria (Zymoseptoria tritici), brown spot (Cochliobolus sativus), wheat leaf brown rust (Puccinia triticina), wheat yellow rust (Puccinia striiformis), corn smut (Ustilago maydis), powdery mildew of grapevine (Uncinula necator), barley scald (Rhynchosporium secalis), rice blast (Magnaporthe oryzae), Asian soybean rust (Phakopsora pachyrhizi), wheat glume blotch (Parastagonospora nodorum), anthracnose of cucurbits (Colletotrichum orbiculare), barley rust (Puccinia hordei), cercospora leaf spot in beet (Cercospora beticola), tomato black spot (Alternaria solani), spot barley reticulata (Pyrenophora teres), wheat powdery mildew (Blumeria graminis f. sp. tritici), barley powdery mildew (Blumeria graminis f. sp.hordei), cucurbit powdery mildew (Erysiphe cichoracearum), cucumber powdery mildew (Podosphaera xanthii), root rot (Rhizoctonia solani), gray mold (Botrytis cinerea), ramularia leaf spot in barley (Ramularia collocygni), wheat yellow spot (Pyrenophora triticirepentis), corn leaf blight (Exserohilum turcicum), corn polysora rust (Puccinia polysora), white mold (Sclerotinia sclerotiorum), soybean powdery mildew (Erysiphe diffusa), apple powdery mildew (Podosphaera leucotricha), soybean anthracnose (Colletotrichum truncatum), soybean leaf blight (Cercospora kikuchii), frog-eye leaf spot of soybean (Cercospora sojina), target spot of soybean (Corynespora). cassiicola) and soybean brown spot (Septoria glycines).

14. Composition, according to claim 13, Petition 870250102165, dated 07 / 11 / 2025, page.161 / 176 6 / 7 characterized by the fact that it treats one of the following diseases caused by the fungal pathogen: Wheat leaf septoria (Zymoseptoria tritici), barley nettle blotch (Pyrenophora teres), ramularia leaf spot in barley (Ramularia collo-cygni), barley scald (Rhynchosporium secalis), barley rust (Puccinia hordei), beet cercospora leaf spot (Cercospora beticola), anthracnose of cucurbits (Colletotrichum orbiculare), rice blast (Magnaporthe oryzae), Asian soybean rust (Phakopsora pachyrhizi), tomato black spot (Alternaria solani), gray mold (Botrytis cinerea), powdery mildew of cucurbits (Podosphaera xanthii), soybean leaf blight (Cercospora kikuchii), Target spot of soybean (Corynespora cassiicola), brown spot of soybean (Septoria glycines), corn smut (Ustilago maydis), and brown leaf rust of wheat (Puccinia triticina).

15. Seed, characterized in that it is treated with a phytologically acceptable amount of the compound defined in any one of claims 1 to 4, or of the composition defined in claim 10.

16. A method for controlling fungal attack on a plant, characterized in that it comprises bringing into contact an area adjacent to the plant, soil adapted to support plant growth, a plant root, plant foliage, and a growing medium adapted to cultivate one plant or one week, with a phytologically acceptable amount of the compound defined in any one of claims 1 to 4, or of the composition defined in claim 10.

17. Compound, characterized in that it is 4-(difluoromethoxy)benzyl 4-amino-2,5-dimethylbenzoate Petition 870250102165, dated 07 / 11 / 2025, page 162 / 176 7 / 7 or acceptable salts, solvates, isotopes or tautomers thereof.

18. A crystalline polymorph form A of the compound of Formula I defined in claim 1, characterized in that the crystalline polymorph form has a powder X-ray diffraction pattern comprising at least two peaks at diffraction angles (2θ) of 5.5 ± 0.2, 12.4 ± 0.2, 21.6 ± 0.2, 23.3 ± 0.2, and 27.1 ± 0.

2.

19. Crystalline polymorph form 1 of the compound defined in claim 3 or 4, characterized in that the crystalline polymorph form has a powder X-ray diffraction pattern comprising at least two peaks at diffraction angles (2θ) of 10.5 ± 0.2, 12.1 ± 0.2, 18.7 ± 0.2, 23.6 ± 0.2, and 25.9 ± 0.

2.

20. Crystalline polymorph form 2 of the compound defined in claim 3 or 4, characterized in that the crystalline polymorph form has a powder X-ray diffraction pattern comprising at least two peaks at diffraction angles (2θ) of 4.9 ± 0.2, 9.6 ± 0.2, 16.1 ± 0.2, 21.6 ± 0.2, and 24.5 ± 0.

2.

21. A crystalline polymorph form 3 of the compound defined in claim 3 or 4, characterized in that the crystalline polymorph form has a powder X-ray diffraction pattern comprising at least two peaks at diffraction angles (2θ) of 4.7 ± 0.2, 9.4 ± 0.2, 19.0 ± 0.2, 21.1 ± 0.2, and 24.7 ± 0.

2. Petition 870250102165, dated 07 / 11 / 2025, pp. 163 / 176